{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:43:06Z","timestamp":1794357786653,"version":"4.9.0"},"reference-count":349,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203786"],"award-info":[{"award-number":["82203786"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403132"],"award-info":[{"award-number":["82403132"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373231"],"award-info":[{"award-number":["82373231"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Science Foundation of Liaoning Province of China","award":["2024-BS-060"],"award-info":[{"award-number":["2024-BS-060"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2024M763669"],"award-info":[{"award-number":["2024M763669"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Breast cancer is a highly heterogeneous disease characterized by diverse molecular subtypes and complex pathogenesis. Recent advances in epigenetics have unveiled the crucial roles of lysine demethylases (KDMs) in modulating gene expression and chromatin dynamics, thereby influencing breast cancer progression, including metastasis, and therapeutic resistance. KDMs, which remove methyl groups from histone lysine residues, are mainly categorized into seven subfamilies (KDM1-7) based on their catalytic mechanisms and substrate specificities. Meanwhile, each subfamily exhibits distinct roles in breast cancer, ranging from transcriptional regulation and chromatin remodeling to interactions with non-histone proteins. Notably, KDMs exhibit subtype-specific functions in breast cancer. KDMs are also implicated in various hallmarks of breast cancer, including DNA damage response, cell cycle regulation, stemness maintenance, metabolic reprogramming, and modulation of the tumor microenvironment. KDMs represent promising targets for overcoming therapeutic resistance in breast cancer. Inhibitors targeting KDMs have shown potential to enhance the efficacy of endocrine therapy, chemotherapy, and targeted therapy by modulating oncogenic signaling pathways. The KDM family members are intricately involved in the molecular pathogenesis of breast cancer, offering a rich landscape for therapeutic intervention. This review summarizes the multifaceted molecular mechanisms and biological functions of KDMs in breast cancer, highlighting their potential as therapeutic targets.<\/jats:p>","DOI":"10.1186\/s12943-025-02512-6","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T10:05:46Z","timestamp":1766484346000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Histone lysine demethylases in breast cancer: molecular mechanisms, biological functions, and therapeutic intervention"],"prefix":"10.1186","volume":"25","author":[{"given":"Anqi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianjun","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mozhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingfan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Litong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"issue":"1","key":"2512_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22024-3","volume":"12","author":"L Garcia-Martinez","year":"2021","unstructured":"Garcia-Martinez L, et al. Epigenetic mechanisms in breast cancer therapy and resistance. Nat Commun. 2021;12(1):1786.","journal-title":"Nat Commun"},{"issue":"1","key":"2512_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","volume":"10","author":"X Xiong","year":"2025","unstructured":"Xiong X, et al. Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther. 2025;10(1):49.","journal-title":"Signal Transduct Target Ther"},{"issue":"10074","key":"2512_CR3","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","volume":"389","author":"N Harbeck","year":"2017","unstructured":"Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389(10074):1134\u201350.","journal-title":"Lancet"},{"issue":"2","key":"2512_CR4","doi-asserted-by":"publisher","first-page":"552","DOI":"10.7150\/ijbs.76187","volume":"19","author":"L Zhang","year":"2023","unstructured":"Zhang L, et al. Targeting breast cancer stem cells. Int J Biol Sci. 2023;19(2):552\u201370.","journal-title":"Int J Biol Sci"},{"issue":"7","key":"2512_CR5","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.cell.2025.02.023","volume":"188","author":"ZH Gray","year":"2025","unstructured":"Gray ZH, et al. 20 years of histone lysine demethylases: from discovery to the clinic and beyond. Cell. 2025;188(7):1747\u201383.","journal-title":"Cell"},{"issue":"1","key":"2512_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01145-1","volume":"7","author":"W Manni","year":"2022","unstructured":"Manni W, et al. JMJD family proteins in cancer and inflammation. Signal Transduct Target Ther. 2022;7(1):304.","journal-title":"Signal Transduct Target Ther"},{"key":"2512_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217093","volume":"598","author":"W Cai","year":"2024","unstructured":"Cai W, et al. Targeting LSD1 in cancer: molecular elucidation and recent advances. Cancer Lett. 2024;598:217093.","journal-title":"Cancer Lett"},{"issue":"4","key":"2512_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3229","volume":"14","author":"V Cortez","year":"2012","unstructured":"Cortez V, et al. Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Res. 2012;14(4):R108.","journal-title":"Breast Cancer Res"},{"issue":"5","key":"2512_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3249","volume":"14","author":"IM Bennani-Baiti","year":"2012","unstructured":"Bennani-Baiti IM. Integration of ER\u03b1-PELP1-HER2 signaling by LSD1 (KDM1A\/AOF2) offers combinatorial therapeutic opportunities to circumventing hormone resistance in breast cancer. Breast Cancer Res. 2012;14(5):112.","journal-title":"Breast Cancer Res"},{"issue":"28","key":"2512_CR10","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1038\/onc.2015.443","volume":"35","author":"UH Park","year":"2016","unstructured":"Park UH, et al. ASXL2 promotes proliferation of breast cancer cells by linking ER\u03b1 to histone methylation. Oncogene. 2016;35(28):3742\u201352.","journal-title":"Oncogene"},{"issue":"12","key":"2512_CR11","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/s41556-023-01281-y","volume":"25","author":"A Llorente","year":"2023","unstructured":"Llorente A, et al. Maf amplification licenses ER\u03b1 through epigenetic remodelling to drive breast cancer metastasis. Nat Cell Biol. 2023;25(12):1833\u201347.","journal-title":"Nat Cell Biol"},{"issue":"44","key":"2512_CR12","doi-asserted-by":"publisher","first-page":"7017","DOI":"10.1038\/s41388-019-0923-2","volume":"38","author":"X Hu","year":"2019","unstructured":"Hu X, et al. LSD1 suppresses invasion, migration and metastasis of luminal breast cancer cells via activation of GATA3 and repression of TRIM37 expression. Oncogene. 2019;38(44):7017\u201334.","journal-title":"Oncogene"},{"issue":"4","key":"2512_CR13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/jmcb\/mjy021","volume":"10","author":"Y Yang","year":"2018","unstructured":"Yang Y, et al. LSD1 coordinates with the SIN3A\/HDAC complex and maintains sensitivity to chemotherapy in breast cancer. J Mol Cell Biol. 2018;10(4):285\u2013301.","journal-title":"J Mol Cell Biol"},{"issue":"21","key":"2512_CR14","doi-asserted-by":"publisher","first-page":"6899","DOI":"10.1158\/0008-5472.CAN-11-1523","volume":"71","author":"Q Li","year":"2011","unstructured":"Li Q, et al. Binding of the JmjC demethylase JARID1B to LSD1\/NuRD suppresses angiogenesis and metastasis in breast cancer cells by repressing chemokine CCL14. Cancer Res. 2011;71(21):6899\u2013908.","journal-title":"Cancer Res"},{"issue":"1","key":"2512_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/onc.2016.186","volume":"36","author":"C Cao","year":"2017","unstructured":"Cao C, et al. Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression. Oncogene. 2017;36(1):133\u201345.","journal-title":"Oncogene"},{"issue":"15","key":"2512_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202004504","volume":"8","author":"Z Gong","year":"2021","unstructured":"Gong Z, et al. OTUD7B deubiquitinates LSD1 to govern its binding partner specificity, homeostasis, and breast cancer metastasis. Adv Sci. 2021;8(15):e2004504.","journal-title":"Adv Sci"},{"issue":"39","key":"2512_CR17","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1038\/onc.2017.158","volume":"36","author":"JY Lee","year":"2017","unstructured":"Lee JY, et al. LSD1 demethylates HIF1\u03b1 to inhibit hydroxylation and ubiquitin-mediated degradation in tumor angiogenesis. Oncogene. 2017;36(39):5512\u201321.","journal-title":"Oncogene"},{"issue":"20","key":"2512_CR18","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1038\/onc.2016.432","volume":"36","author":"J Feng","year":"2017","unstructured":"Feng J. Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms. Oncogene. 2017;36(20):2775\u201390.","journal-title":"Oncogene"},{"issue":"6","key":"2512_CR19","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.celrep.2019.10.004","volume":"29","author":"Y Zeng","year":"2019","unstructured":"Zeng Y, et al. Regulation of EZH2 by SMYD2-mediated lysine methylation is implicated in tumorigenesis. Cell Rep. 2019;29(6):1482-1498.e4.","journal-title":"Cell Rep"},{"issue":"11","key":"2512_CR20","doi-asserted-by":"publisher","first-page":"6154","DOI":"10.1093\/nar\/gkac494","volume":"50","author":"AJ McIntyre","year":"2022","unstructured":"McIntyre AJ, et al. TBX2 acts as a potent transcriptional silencer of tumour suppressor genes through interaction with the CoREST complex to sustain the proliferation of breast cancers. Nucleic Acids Res. 2022;50(11):6154\u201373.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2512_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00702-5","volume":"8","author":"L Li","year":"2017","unstructured":"Li L, et al. ZNF516 suppresses EGFR by targeting the CtBP\/LSD1\/CoREST complex to chromatin. Nat Commun. 2017;8(1):691.","journal-title":"Nat Commun"},{"issue":"4","key":"2512_CR22","doi-asserted-by":"publisher","first-page":"972","DOI":"10.7150\/thno.22328","volume":"8","author":"Y Zheng","year":"2018","unstructured":"Zheng Y, et al. The homeotic protein SIX3 suppresses carcinogenesis and metastasis through recruiting the LSD1\/NuRD(MTA3) complex. Theranostics. 2018;8(4):972\u201389.","journal-title":"Theranostics"},{"issue":"4","key":"2512_CR23","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.cell.2009.05.050","volume":"138","author":"Y Wang","year":"2009","unstructured":"Wang Y, et al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell. 2009;138(4):660\u201372.","journal-title":"Cell"},{"issue":"4","key":"2512_CR24","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.molcel.2018.07.039","volume":"71","author":"Y Tan","year":"2018","unstructured":"Tan Y, et al. Dismissal of RNA polymerase II underlies a large ligand-induced enhancer decommissioning program. Mol Cell. 2018;71(4):526-539.e8.","journal-title":"Mol Cell"},{"key":"2512_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2023.115132","volume":"262","author":"Z Li","year":"2023","unstructured":"Li Z, et al. KDM2A interacts with estrogen receptor \u03b1 to promote bisphenol A and S-induced breast cancer cell proliferation by repressing TET2 expression. Ecotoxicol Environ Saf. 2023;262:115132.","journal-title":"Ecotoxicol Environ Saf"},{"key":"2512_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cells9102266","author":"Y Tanaka","year":"2020","unstructured":"Tanaka Y, et al. Production of ROS by Gallic acid activates KDM2A to reduce rRNA transcription. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9102266.","journal-title":"Cells"},{"key":"2512_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/biom12010030","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y, Tsuneoka M. Gallic acid derivatives propyl gallate and epigallocatechin gallate reduce rRNA transcription via induction of KDM2A activation. Biomolecules. 2021. https:\/\/doi.org\/10.3390\/biom12010030.","journal-title":"Biomolecules"},{"issue":"7","key":"2512_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100888","volume":"9","author":"W Rizwani","year":"2014","unstructured":"Rizwani W, et al. Mammalian lysine histone demethylase KDM2A regulates E2F1-mediated gene transcription in breast cancer cells. PLoS One. 2014;9(7):e100888.","journal-title":"PLoS One"},{"issue":"8","key":"2512_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2017.71","volume":"6","author":"JY Chen","year":"2017","unstructured":"Chen JY, et al. Lysine demethylase KDM2A inhibits TET2 to promote DNA methylation and silencing of tumor suppressor genes in breast cancer. Oncogenesis. 2017;6(8):e369.","journal-title":"Oncogenesis"},{"key":"2512_CR30","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.canlet.2021.01.007","volume":"502","author":"Y Yang","year":"2021","unstructured":"Yang Y, et al. FBXL10 promotes ERR\u03b1 protein stability and proliferation of breast cancer cells by enhancing the mono-ubiquitylation of ERR\u03b1. Cancer Lett. 2021;502:108\u201319.","journal-title":"Cancer Lett"},{"issue":"9","key":"2512_CR31","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/abbs\/gmy084","volume":"50","author":"Q Zheng","year":"2018","unstructured":"Zheng Q, et al. Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing p15INK4B, p16INK4A, and p57KIP2 transcription. Acta Biochim Biophys Sin. 2018;50(9):897\u2013904.","journal-title":"Acta Biochim Biophys Sin"},{"key":"2512_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155719","volume":"150","author":"E Chavdoula","year":"2024","unstructured":"Chavdoula E, et al. Transcriptional regulation of amino acid metabolism by KDM2B, in the context of ncPRC1.1 and in concert with MYC and ATF4. Metabolism. 2024;150:155719.","journal-title":"Metabolism"},{"issue":"14","key":"2512_CR33","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1158\/0008-5472.CAN-13-2733","volume":"74","author":"F Kottakis","year":"2014","unstructured":"Kottakis F, et al. NDY1\/KDM2B functions as a master regulator of polycomb complexes and controls self-renewal of breast cancer stem cells. Cancer Res. 2014;74(14):3935\u201346.","journal-title":"Cancer Res"},{"issue":"8","key":"2512_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05187-9","volume":"13","author":"M Shen","year":"2022","unstructured":"Shen M, et al. Hepatic ARID3A facilitates liver cancer malignancy by cooperating with CEP131 to regulate an embryonic stem cell-like gene signature. Cell Death Dis. 2022;13(8):732.","journal-title":"Cell Death Dis"},{"key":"2512_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081122","author":"D Jones","year":"2019","unstructured":"Jones D, et al. The histone demethylase enzymes KDM3A and KDM4B co-operatively regulate chromatin transactions of the estrogen receptor in breast cancer. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11081122.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2512_CR36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2206878120","volume":"120","author":"C Guo","year":"2023","unstructured":"Guo C, et al. The SET oncoprotein promotes estrogen-induced transcription by facilitating establishment of active chromatin. Proc Natl Acad Sci USA. 2023;120(8):e2206878120.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2512_CR37","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/nar\/gku1298","volume":"43","author":"MA Wade","year":"2015","unstructured":"Wade MA, et al. The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer. Nucleic Acids Res. 2015;43(1):196\u2013207.","journal-title":"Nucleic Acids Res"},{"issue":"41","key":"2512_CR38","doi-asserted-by":"publisher","first-page":"28179","DOI":"10.1074\/jbc.M114.584425","volume":"289","author":"K Mahajan","year":"2014","unstructured":"Mahajan K, et al. ACK1 tyrosine kinase interacts with histone demethylase KDM3A to regulate the mammary tumor oncogene HOXA1. J Biol Chem. 2014;289(41):28179\u201391.","journal-title":"J Biol Chem"},{"issue":"1","key":"2512_CR39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/onc.2016.174","volume":"36","author":"S Ramadoss","year":"2017","unstructured":"Ramadoss S, Guo G, Wang CY. Lysine demethylase KDM3A regulates breast cancer cell invasion and apoptosis by targeting histone and the non-histone protein p53. Oncogene. 2017;36(1):47\u201359.","journal-title":"Oncogene"},{"key":"2512_CR40","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.16844","author":"VE Pedanou","year":"2016","unstructured":"Pedanou VE, et al. The histone H3K9 demethylase KDM3A promotes anoikis by transcriptionally activating pro-apoptotic genes BNIP3 and BNIP3L. Elife. 2016. https:\/\/doi.org\/10.7554\/eLife.16844.","journal-title":"Elife"},{"issue":"46","key":"2512_CR41","doi-asserted-by":"publisher","first-page":"11766","DOI":"10.1073\/pnas.1805662115","volume":"115","author":"H Kim","year":"2018","unstructured":"Kim H, et al. KDM3A histone demethylase functions as an essential factor for activation of JAK2-STAT3 signaling pathway. Proc Natl Acad Sci U S A. 2018;115(46):11766\u201371.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2512_CR42","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1158\/0008-5472.CAN-20-3317","volume":"81","author":"A Bhan","year":"2021","unstructured":"Bhan A, et al. Inhibition of Jumonji Histone Demethylases selectively suppresses HER2(+) breast leptomeningeal carcinomatosis growth via inhibition of GMCSF expression. Cancer Res. 2021;81(12):3200\u201314.","journal-title":"Cancer Res"},{"issue":"11","key":"2512_CR43","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1038\/cdd.2016.92","volume":"23","author":"J Wang","year":"2016","unstructured":"Wang J, et al. Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy. Cell Death Differ. 2016;23(11):1886\u201396.","journal-title":"Cell Death Differ"},{"issue":"3","key":"2512_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3667","volume":"16","author":"LL Li","year":"2014","unstructured":"Li LL, et al. JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI. Breast Cancer Res. 2014;16(3):R56.","journal-title":"Breast Cancer Res"},{"issue":"16","key":"2512_CR45","doi-asserted-by":"publisher","first-page":"6456","DOI":"10.1158\/0008-5472.CAN-10-0413","volume":"70","author":"J Yang","year":"2010","unstructured":"Yang J, et al. The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth. Cancer Res. 2010;70(16):6456\u201366.","journal-title":"Cancer Res"},{"issue":"18","key":"2512_CR46","doi-asserted-by":"publisher","first-page":"7541","DOI":"10.1073\/pnas.1017374108","volume":"108","author":"L Shi","year":"2011","unstructured":"Shi L, et al. Histone demethylase JMJD2B coordinates H3K4\/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. Proc Natl Acad Sci U S A. 2011;108(18):7541\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"49","key":"2512_CR47","doi-asserted-by":"publisher","first-page":"E3367","DOI":"10.1073\/pnas.1217394109","volume":"109","author":"W Luo","year":"2012","unstructured":"Luo W, et al. Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression. Proc Natl Acad Sci U S A. 2012;109(49):E3367-76.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"50","key":"2512_CR48","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1038\/onc.2009.297","volume":"28","author":"G Liu","year":"2009","unstructured":"Liu G, et al. Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene. 2009;28(50):4491\u2013500.","journal-title":"Oncogene"},{"key":"2512_CR49","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx207","author":"HJ Choi","year":"2018","unstructured":"Choi HJ, et al. Role of RBP2-induced ER and IGF1R-ErbB signaling in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2018. https:\/\/doi.org\/10.1093\/jnci\/djx207.","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"2512_CR50","doi-asserted-by":"publisher","first-page":"7313","DOI":"10.1074\/jbc.M115.701227","volume":"291","author":"RA Varier","year":"2016","unstructured":"Varier RA, et al. Recruitment of the mammalian histone-modifying EMSY complex to target genes is regulated by ZNF131. J Biol Chem. 2016;291(14):7313\u201324.","journal-title":"J Biol Chem"},{"issue":"4","key":"2512_CR51","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s10565-022-09754-w","volume":"39","author":"S Li","year":"2023","unstructured":"Li S, et al. Fbxo22 inhibits metastasis in triple-negative breast cancer through ubiquitin modification of KDM5A and regulation of H3K4me3 demethylation. Cell Biol Toxicol. 2023;39(4):1641\u201355.","journal-title":"Cell Biol Toxicol"},{"issue":"6","key":"2512_CR52","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ccell.2018.10.014","volume":"34","author":"K Hinohara","year":"2018","unstructured":"Hinohara K, et al. KDM5 histone demethylase activity links cellular transcriptomic heterogeneity to therapeutic resistance. Cancer Cell. 2018;34(6):939-953.e9.","journal-title":"Cancer Cell"},{"issue":"11","key":"2512_CR53","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/s41588-022-01212-x","volume":"54","author":"X Liu","year":"2022","unstructured":"Liu X, et al. Histone H3 proline 16 hydroxylation regulates mammalian gene expression. Nat Genet. 2022;54(11):1721\u201335.","journal-title":"Nat Genet"},{"issue":"6","key":"2512_CR54","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.ccr.2014.04.024","volume":"25","author":"S Yamamoto","year":"2014","unstructured":"Yamamoto S, et al. JARID1B is a luminal lineage-driving oncogene in breast cancer. Cancer Cell. 2014;25(6):762\u201377.","journal-title":"Cancer Cell"},{"issue":"2","key":"2512_CR55","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/ijc.22673","volume":"121","author":"A Barrett","year":"2007","unstructured":"Barrett A, et al. Breast cancer associated transcriptional repressor PLU-1\/JARID1B interacts directly with histone deacetylases. Int J Cancer. 2007;121(2):265\u201375.","journal-title":"Int J Cancer"},{"issue":"9","key":"2512_CR56","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1128\/MCB.06373-11","volume":"32","author":"PP Wong","year":"2012","unstructured":"Wong PP, et al. Histone demethylase KDM5B collaborates with TFAP2C and Myc to repress the cell cycle inhibitor p21(cip) (CDKN1A). Mol Cell Biol. 2012;32(9):1633\u201344.","journal-title":"Mol Cell Biol"},{"issue":"2","key":"2512_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101396","volume":"5","author":"CC Liu","year":"2024","unstructured":"Liu CC, et al. Targeting EMSY-mediated methionine metabolism is a potential therapeutic strategy for triple-negative breast cancer. Cell Rep Med. 2024;5(2):101396.","journal-title":"Cell Rep Med"},{"issue":"6","key":"2512_CR58","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.molcel.2007.03.001","volume":"25","author":"K Yamane","year":"2007","unstructured":"Yamane K, et al. PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell. 2007;25(6):801\u201312.","journal-title":"Mol Cell"},{"key":"2512_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101320","volume":"16","author":"R Kadamb","year":"2022","unstructured":"Kadamb R, et al. Invasive phenotype in triple negative breast cancer is inhibited by blocking SIN3A-PF1 interaction through KLF9 mediated repression of ITGA6 and ITGB1. Transl Oncol. 2022;16:101320.","journal-title":"Transl Oncol"},{"issue":"1","key":"2512_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1228-7","volume":"21","author":"MM Montano","year":"2019","unstructured":"Montano MM, et al. Inhibition of the histone demethylase, KDM5B, directly induces re-expression of tumor suppressor protein HEXIM1 in cancer cells. Breast Cancer Res. 2019;21(1):138.","journal-title":"Breast Cancer Res"},{"key":"2512_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.114033","volume":"157","author":"H Zheng","year":"2023","unstructured":"Zheng H, et al. Epigenetically suppressed tumor cell intrinsic STING promotes tumor immune escape. Biomed Pharmacother. 2023;157:114033.","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"2512_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.2006134","volume":"16","author":"L Wu","year":"2018","unstructured":"Wu L, et al. KDM5 histone demethylases repress immune response via suppression of STING. PLoS Biol. 2018;16(8):e2006134.","journal-title":"PLoS Biol"},{"issue":"2","key":"2512_CR63","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.yexcr.2019.04.006","volume":"379","author":"ZG Zhang","year":"2019","unstructured":"Zhang ZG, et al. KDM5B promotes breast cancer cell proliferation and migration via AMPK-mediated lipid metabolism reprogramming. Exp Cell Res. 2019;379(2):182\u201390.","journal-title":"Exp Cell Res"},{"key":"2512_CR64","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqac110","author":"L Li","year":"2022","unstructured":"Li L, et al. CUX2\/KDM5B\/SOX17 axis affects the occurrence and development of breast cancer. Endocrinology. 2022. https:\/\/doi.org\/10.1210\/endocr\/bqac110.","journal-title":"Endocrinology"},{"issue":"10","key":"2512_CR65","doi-asserted-by":"publisher","first-page":"8025","DOI":"10.1007\/s13277-015-3547-3","volume":"36","author":"DY Fu","year":"2015","unstructured":"Fu DY, et al. Decreased expression of SOX17 is associated with tumor progression and poor prognosis in breast cancer. Tumour Biol. 2015;36(10):8025\u201334.","journal-title":"Tumour Biol"},{"issue":"9","key":"2512_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202004635","volume":"8","author":"HF Shen","year":"2021","unstructured":"Shen HF, et al. The dual function of KDM5C in both gene transcriptional activation and repression promotes breast cancer cell growth and tumorigenesis. Adv Sci. 2021;8(9):2004635.","journal-title":"Adv Sci"},{"issue":"12","key":"2512_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03129-x","volume":"11","author":"S Mukherjee","year":"2020","unstructured":"Mukherjee S, et al. Suppression of poised oncogenes by ZMYND8 promotes chemo-sensitization. Cell Death Dis. 2020;11(12):1073.","journal-title":"Cell Death Dis"},{"issue":"10","key":"2512_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05296-5","volume":"13","author":"Q Xiao","year":"2022","unstructured":"Xiao Q, et al. Regulation of KDM5C stability and enhancer reprogramming in breast cancer. Cell Death Dis. 2022;13(10):843.","journal-title":"Cell Death Dis"},{"issue":"39","key":"2512_CR69","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.1038\/onc.2017.157","volume":"36","author":"G Xie","year":"2017","unstructured":"Xie G, et al. UTX promotes hormonally responsive breast carcinogenesis through feed-forward transcription regulation with estrogen receptor. Oncogene. 2017;36(39):5497\u2013511.","journal-title":"Oncogene"},{"issue":"11","key":"2512_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2062-7","volume":"10","author":"W Yu","year":"2019","unstructured":"Yu W, et al. GATA3 recruits UTX for gene transcriptional activation to suppress metastasis of breast cancer. Cell Death Dis. 2019;10(11):832.","journal-title":"Cell Death Dis"},{"key":"2512_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6203","volume":"5","author":"T van den Beucken","year":"2014","unstructured":"van den Beucken T, et al. Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nat Commun. 2014;5:5203.","journal-title":"Nat Commun"},{"issue":"6","key":"2512_CR72","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1158\/0008-5472.CAN-13-1896","volume":"74","author":"JH Kim","year":"2014","unstructured":"Kim JH, et al. UTX and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells. Cancer Res. 2014;74(6):1705\u201317.","journal-title":"Cancer Res"},{"issue":"6","key":"2512_CR73","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.7150\/thno.70581","volume":"12","author":"J Lan","year":"2022","unstructured":"Lan J, et al. Chemotherapy-induced adenosine A2B receptor expression mediates epigenetic regulation of pluripotency factors and promotes breast cancer stemness. Theranostics. 2022;12(6):2598\u2013612.","journal-title":"Theranostics"},{"issue":"7","key":"2512_CR74","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1038\/s41556-024-01446-3","volume":"26","author":"M Seehawer","year":"2024","unstructured":"Seehawer M, et al. Loss of Kmt2c or Kmt2d drives brain metastasis via KDM6A-dependent upregulation of MMP3. Nat Cell Biol. 2024;26(7):1165\u201375.","journal-title":"Nat Cell Biol"},{"issue":"4","key":"2512_CR75","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1158\/1541-7786.MCR-21-0402","volume":"20","author":"JF Xiao","year":"2022","unstructured":"Xiao JF, et al. KDM6A depletion in breast epithelial cells leads to reduced sensitivity to anticancer agents and increased TGF\u03b2 activity. Mol Cancer Res. 2022;20(4):637\u201349.","journal-title":"Mol Cancer Res"},{"issue":"9","key":"2512_CR76","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1172\/JCI138577","volume":"130","author":"H Lu","year":"2020","unstructured":"Lu H, et al. Chemotherapy-induced S100A10 recruits KDM6A to facilitate OCT4-mediated breast cancer stemness. J Clin Invest. 2020;130(9):4607\u201323.","journal-title":"J Clin Invest"},{"issue":"12","key":"2512_CR77","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1093\/stcltm\/szad061","volume":"12","author":"GL Semenza","year":"2023","unstructured":"Semenza GL. Mechanisms of breast cancer stem cell specification and self-renewal mediated by hypoxia-inducible factor 1. Stem Cells Transl Med. 2023;12(12):783\u201390.","journal-title":"Stem Cells Transl Med"},{"issue":"10","key":"2512_CR78","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.15252\/embr.201540244","volume":"16","author":"HJ Choi","year":"2015","unstructured":"Choi HJ, et al. UTX inhibits EMT-induced breast CSC properties by epigenetic repression of EMT genes in cooperation with LSD1 and HDAC1. EMBO Rep. 2015;16(10):1288\u201398.","journal-title":"EMBO Rep"},{"issue":"9","key":"2512_CR79","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1158\/1535-7163.MCT-17-0802","volume":"17","author":"W Wang","year":"2018","unstructured":"Wang W, et al. KDM6B counteracts EZH2-mediated suppression of IGFBP5 to confer resistance to PI3K\/AKT inhibitor treatment in breast cancer. Mol Cancer Ther. 2018;17(9):1973\u201383.","journal-title":"Mol Cancer Ther"},{"issue":"19","key":"2512_CR80","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1038\/emboj.2011.284","volume":"30","author":"A Svotelis","year":"2011","unstructured":"Svotelis A, et al. H3K27 demethylation by JMJD3 at a poised enhancer of anti-apoptotic gene BCL2 determines ER\u03b1 ligand dependency. EMBO J. 2011;30(19):3947\u201361.","journal-title":"EMBO J"},{"key":"2512_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16061118","author":"N Duan","year":"2024","unstructured":"Duan N, et al. An imbalance in histone modifiers induces tRNA-Cys-GCA overexpression and tRF-27 accumulation by attenuating promoter H3K27me3 in primary Trastuzumab-resistant breast cancer. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16061118.","journal-title":"Cancers (Basel)"},{"issue":"53","key":"2512_CR82","doi-asserted-by":"publisher","first-page":"44508","DOI":"10.1074\/jbc.M112.424903","volume":"287","author":"S Ramadoss","year":"2012","unstructured":"Ramadoss S, Chen X, Wang CY. Histone demethylase KDM6B promotes epithelial-mesenchymal transition. J Biol Chem. 2012;287(53):44508\u201317.","journal-title":"J Biol Chem"},{"issue":"2","key":"2512_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2022.166611","volume":"1869","author":"L Du","year":"2023","unstructured":"Du L, et al. KDM6B regulates M2 polarization of macrophages by modulating the stability of nuclear \u03b2-catenin. Biochimica et Biophysica Acta (BBA). 2023;1869(2):166611.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"14","key":"2512_CR84","doi-asserted-by":"publisher","first-page":"6847","DOI":"10.7150\/thno.51864","volume":"11","author":"J Xun","year":"2021","unstructured":"Xun J, et al. Cancer-derived exosomal miR-138-5p modulates polarization of tumor-associated macrophages through inhibition of KDM6B. Theranostics. 2021;11(14):6847\u201359.","journal-title":"Theranostics"},{"key":"2512_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.664375","volume":"9","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, et al. The jumonji domain-containing histone demethylase homolog 1D\/lysine demethylase 7A (JHDM1D\/KDM7A) is an epigenetic activator of RHOJ transcription in breast cancer cells. Front Cell Dev Biol. 2021;9:664375.","journal-title":"Front Cell Dev Biol"},{"key":"2512_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.102612","volume":"51","author":"Q Liu","year":"2020","unstructured":"Liu Q, et al. Contribution of synergism between PHF8 and HER2 signalling to breast cancer development and drug resistance. EBioMedicine. 2020;51:102612.","journal-title":"EBioMedicine"},{"key":"2512_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107945","volume":"153","author":"JJ Shi","year":"2024","unstructured":"Shi JJ, et al. Structure-based identification of a potent KDM7A inhibitor exerts anticancer activity through transcriptionally reducing MKRN1 in taxol- resistant and -sensitive triple-negative breast cancer cells. Bioorg Chem. 2024;153:107945.","journal-title":"Bioorg Chem"},{"issue":"2","key":"2512_CR88","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/jcp.29008","volume":"235","author":"Z Meng","year":"2020","unstructured":"Meng Z, et al. Histone demethylase KDM7A is required for stem cell maintenance and apoptosis inhibition in breast cancer. J Cell Physiol. 2020;235(2):932\u201343.","journal-title":"J Cell Physiol"},{"issue":"6","key":"2512_CR89","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1172\/JCI85747","volume":"126","author":"Q Wang","year":"2016","unstructured":"Wang Q, et al. Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis. J Clin Invest. 2016;126(6):2205\u201320.","journal-title":"J Clin Invest"},{"issue":"4","key":"2512_CR90","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1093\/nar\/gkw1093","volume":"45","author":"P Shao","year":"2017","unstructured":"Shao P, et al. Histone demethylase PHF8 promotes epithelial to mesenchymal transition and breast tumorigenesis. Nucleic Acids Res. 2017;45(4):1687\u2013702.","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"2512_CR91","doi-asserted-by":"publisher","first-page":"5603","DOI":"10.1172\/JCI121679","volume":"128","author":"Y Johmura","year":"2018","unstructured":"Johmura Y, et al. Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer. J Clin Invest. 2018;128(12):5603\u201319.","journal-title":"J Clin Invest"},{"issue":"12","key":"2512_CR92","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1016\/j.celrep.2016.05.046","volume":"15","author":"JM Spangle","year":"2016","unstructured":"Spangle JM, et al. PI3K\/AKT signaling regulates H3K4 methylation in breast cancer. Cell Rep. 2016;15(12):2692\u2013704.","journal-title":"Cell Rep"},{"issue":"7","key":"2512_CR93","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2307150121","volume":"121","author":"B Dong","year":"2024","unstructured":"Dong B, et al. RNF20 contributes to epigenetic immunosuppression through CDK9-dependent LSD1 stabilization. Proc Natl Acad Sci U S A. 2024;121(7):e2307150121.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2512_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2025.02.016","author":"A Li","year":"2025","unstructured":"Li A, et al. Lactylation of LSD1 is an acquired epigenetic vulnerability of BRAFi\/MEKi-resistant melanoma. Dev Cell. 2025. https:\/\/doi.org\/10.1016\/j.devcel.2025.02.016.","journal-title":"Dev Cell"},{"issue":"4","key":"2512_CR95","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ajpath.2022.12.010","volume":"193","author":"X Li","year":"2023","unstructured":"Li X, et al. YTHDF2 regulates cell growth and cycle by facilitating KDM1A mRNA stability. Am J Pathol. 2023;193(4):442\u201355.","journal-title":"Am J Pathol"},{"issue":"6","key":"2512_CR96","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1142\/S0192415X18500702","volume":"46","author":"J Ham","year":"2018","unstructured":"Ham J, et al. Genome-Wide Methylation Analysis Identifies NOX4 and KDM5A as Key Regulators in Inhibiting Breast Cancer Cell Proliferation by Ginsenoside Rg3. Am J Chin Med. 2018;46(6):1333\u201355.","journal-title":"Am J Chin Med"},{"issue":"4","key":"2512_CR97","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1111\/cas.13925","volume":"110","author":"I Mocavini","year":"2019","unstructured":"Mocavini I, et al. Jarid1B expression and its function in DNA damage repair are tightly regulated by miRNAs in breast cancer. Cancer Sci. 2019;110(4):1232\u201343.","journal-title":"Cancer Sci"},{"issue":"5992","key":"2512_CR98","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1126\/science.1192002","volume":"329","author":"MC Tsai","year":"2010","unstructured":"Tsai MC, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science. 2010;329(5992):689\u201393.","journal-title":"Science"},{"issue":"7","key":"2512_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2729-0","volume":"11","author":"Y Lian","year":"2020","unstructured":"Lian Y, et al. Long intergenic non-protein-coding RNA 01446 facilitates the proliferation and metastasis of gastric cancer cells through interacting with the histone lysine-specific demethylase LSD1. Cell Death Dis. 2020;11(7):522.","journal-title":"Cell Death Dis"},{"issue":"4","key":"2512_CR100","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.molcel.2012.11.006","volume":"48","author":"JC Black","year":"2012","unstructured":"Black JC, Van Rechem C, Whetstine JR. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol Cell. 2012;48(4):491\u2013507.","journal-title":"Mol Cell"},{"key":"2512_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216779","volume":"587","author":"S Chakraborty","year":"2024","unstructured":"Chakraborty S, et al. Molecular mechanisms in regulation of autophagy and apoptosis in view of epigenetic regulation of genes and involvement of liquid-liquid phase separation. Cancer Lett. 2024;587:216779.","journal-title":"Cancer Lett"},{"issue":"1","key":"2512_CR102","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-021-00737-3","volume":"28","author":"D Kim","year":"2021","unstructured":"Kim D, Kim KI, Baek SH. Roles of lysine-specific demethylase 1 (LSD1) in homeostasis and diseases. J Biomed Sci. 2021;28(1):41.","journal-title":"J Biomed Sci"},{"issue":"6","key":"2512_CR103","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.18632\/aging.102887","volume":"12","author":"E Cuy\u00e0s","year":"2020","unstructured":"Cuy\u00e0s E, et al. The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes. Aging (Albany NY). 2020;12(6):4794\u2013814.","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"2512_CR104","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06270-3","volume":"23","author":"Y Xi","year":"2025","unstructured":"Xi Y, et al. Super-enhancer-hijacking RBBP7 potentiates metastasis and stemness of breast cancer via recruiting NuRD complex subunit LSD1. J Transl Med. 2025;23(1):266.","journal-title":"J Transl Med"},{"issue":"1","key":"2512_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48607-4","volume":"15","author":"F Qiu","year":"2024","unstructured":"Qiu F, et al. Priming with LSD1 inhibitors promotes the persistence and antitumor effect of adoptively transferred T cells. Nat Commun. 2024;15(1):4327.","journal-title":"Nat Commun"},{"issue":"1","key":"2512_CR106","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-023-00952-0","volume":"30","author":"MAA Mamun","year":"2023","unstructured":"Mamun MAA, et al. LSD1: an emerging face in altering the tumor microenvironment and enhancing immune checkpoint therapy. J Biomed Sci. 2023;30(1):60.","journal-title":"J Biomed Sci"},{"issue":"3","key":"2512_CR107","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41388-018-0451-5","volume":"38","author":"Y Qin","year":"2019","unstructured":"Qin Y, et al. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. Oncogene. 2019;38(3):390\u2013405.","journal-title":"Oncogene"},{"issue":"21","key":"2512_CR108","doi-asserted-by":"publisher","first-page":"5900","DOI":"10.1158\/0008-5472.CAN-17-1754","volume":"77","author":"E Metzger","year":"2017","unstructured":"Metzger E, et al. KDM4 inhibition targets breast cancer stem-like cells. Cancer Res. 2017;77(21):5900\u201312.","journal-title":"Cancer Res"},{"issue":"4","key":"2512_CR109","first-page":"1519","volume":"5","author":"Q Ye","year":"2015","unstructured":"Ye Q, et al. Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer. Am J Cancer Res. 2015;5(4):1519\u201330.","journal-title":"Am J Cancer Res"},{"issue":"15","key":"2512_CR110","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1038\/s41388-018-0620-6","volume":"38","author":"G Paroni","year":"2019","unstructured":"Paroni G, et al. HER2-positive breast-cancer cell lines are sensitive to KDM5 inhibition: definition of a gene-expression model for the selection of sensitive cases. Oncogene. 2019;38(15):2675\u201389.","journal-title":"Oncogene"},{"issue":"5","key":"2512_CR111","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1158\/0008-5472.CAN-17-1453","volume":"78","author":"BR Leadem","year":"2018","unstructured":"Leadem BR, et al. A KDM5 inhibitor increases global H3K4 trimethylation occupancy and enhances the biological efficacy of 5-aza-2\u2019-deoxycytidine. Cancer Res. 2018;78(5):1127\u201339.","journal-title":"Cancer Res"},{"issue":"2","key":"2512_CR112","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.yexcr.2017.08.024","volume":"359","author":"N Yan","year":"2017","unstructured":"Yan N, et al. Gskj4, an H3K27me3 demethylase inhibitor, effectively suppresses the breast cancer stem cells. Exp Cell Res. 2017;359(2):405\u201314.","journal-title":"Exp Cell Res"},{"issue":"7","key":"2512_CR113","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.cell.2004.12.012","volume":"119","author":"Y Shi","year":"2004","unstructured":"Shi Y, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119(7):941\u201353.","journal-title":"Cell"},{"issue":"5","key":"2512_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103519","volume":"28","author":"L Zhang","year":"2023","unstructured":"Zhang L, et al. Development of JmjC-domain-containing histone demethylase (KDM2-7) inhibitors for cancer therapy. Drug Discov Today. 2023;28(5):103519.","journal-title":"Drug Discov Today"},{"issue":"7262","key":"2512_CR115","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature08315","volume":"461","author":"DN Ciccone","year":"2009","unstructured":"Ciccone DN, et al. KDM1B is a histone H3K4 demethylase required to establish maternal genomic imprints. Nature. 2009;461(7262):415\u20138.","journal-title":"Nature"},{"issue":"47","key":"2512_CR116","doi-asserted-by":"publisher","first-page":"81737","DOI":"10.18632\/oncotarget.19387","volume":"8","author":"L Chen","year":"2017","unstructured":"Chen L, et al. Functional characterization of lysine-specific demethylase 2 (LSD2\/KDM1B) in breast cancer progression. Oncotarget. 2017;8(47):81737\u201353.","journal-title":"Oncotarget"},{"issue":"9","key":"2512_CR117","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41590-022-01290-3","volume":"23","author":"M Musella","year":"2022","unstructured":"Musella M, et al. Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B. Nat Immunol. 2022;23(9):1379\u201392.","journal-title":"Nat Immunol"},{"issue":"7138","key":"2512_CR118","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/nature05671","volume":"446","author":"J Wang","year":"2007","unstructured":"Wang J, et al. Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature. 2007;446(7138):882\u20137.","journal-title":"Nature"},{"issue":"7057","key":"2512_CR119","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/nature04021","volume":"437","author":"MG Lee","year":"2005","unstructured":"Lee MG, et al. An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature. 2005;437(7057):432\u20135.","journal-title":"Nature"},{"issue":"7057","key":"2512_CR120","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature04020","volume":"437","author":"E Metzger","year":"2005","unstructured":"Metzger E, et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature. 2005;437(7057):436\u20139.","journal-title":"Nature"},{"issue":"3","key":"2512_CR121","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.cell.2006.12.038","volume":"128","author":"I Garcia-Bassets","year":"2007","unstructured":"Garcia-Bassets I, et al. Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors. Cell. 2007;128(3):505\u201318.","journal-title":"Cell"},{"issue":"24","key":"2512_CR122","doi-asserted-by":"publisher","first-page":"11259","DOI":"10.1158\/0008-5472.CAN-05-2495","volume":"65","author":"R Mehra","year":"2005","unstructured":"Mehra R, et al. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res. 2005;65(24):11259\u201364.","journal-title":"Cancer Res"},{"issue":"7418","key":"2512_CR123","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Comprehensive molecular portraits of human breast tumours","year":"2012","unstructured":"Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61\u201370.","journal-title":"Nature"},{"issue":"7757","key":"2512_CR124","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41586-019-1056-z","volume":"569","author":"F Bertucci","year":"2019","unstructured":"Bertucci F, et al. Genomic characterization of metastatic breast cancers. Nature. 2019;569(7757):560\u20134.","journal-title":"Nature"},{"key":"2512_CR125","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.1016\/j.ijbiomac.2020.08.221","volume":"164","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, et al. The R251Q mutation of LSD1 promotes invasion and migration of luminal breast cancer cells. Int J Biol Macromol. 2020;164:4000\u20139.","journal-title":"Int J Biol Macromol"},{"issue":"5","key":"2512_CR126","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/ng.2935","volume":"46","author":"DC Lin","year":"2014","unstructured":"Lin DC, et al. Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet. 2014;46(5):467\u201373.","journal-title":"Nat Genet"},{"issue":"16","key":"2512_CR127","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1038\/onc.2016.377","volume":"36","author":"M Hazawa","year":"2017","unstructured":"Hazawa M, et al. ZNF750 is a lineage-specific tumour suppressor in squamous cell carcinoma. Oncogene. 2017;36(16):2243\u201354.","journal-title":"Oncogene"},{"issue":"22","key":"2512_CR128","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1038\/s41388-020-1277-5","volume":"39","author":"M Cassandri","year":"2020","unstructured":"Cassandri M, et al. ZNF750 represses breast cancer invasion via epigenetic control of prometastatic genes. Oncogene. 2020;39(22):4331\u201343.","journal-title":"Oncogene"},{"issue":"3","key":"2512_CR129","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/carcin\/bgp324","volume":"31","author":"S Lim","year":"2010","unstructured":"Lim S, et al. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis. 2010;31(3):512\u201320.","journal-title":"Carcinogenesis"},{"issue":"1","key":"2512_CR130","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-024-03225-2","volume":"43","author":"X Bai","year":"2024","unstructured":"Bai X, et al. METTL14 suppresses the expression of YAP1 and the stemness of triple-negative breast cancer. J Exp Clin Cancer Res. 2024;43(1):307.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"2512_CR131","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3892\/ol.2020.12363","volume":"21","author":"K Zhao","year":"2021","unstructured":"Zhao K, et al. Comparison of the expression levels of lysine-specific demethylase 1 and survival outcomes between triple-negative and non-triple-negative breast cancer. Oncol Lett. 2021;21(2):102.","journal-title":"Oncol Lett"},{"issue":"2","key":"2512_CR132","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118002","volume":"10","author":"S Nagasawa","year":"2015","unstructured":"Nagasawa S, et al. LSD1 overexpression is associated with poor prognosis in basal-like breast cancer, and sensitivity to PARP inhibition. PLoS ONE. 2015;10(2):e0118002.","journal-title":"PLoS ONE"},{"issue":"7078","key":"2512_CR133","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/nature04433","volume":"439","author":"Y Tsukada","year":"2006","unstructured":"Tsukada Y, et al. Histone demethylation by a family of JmjC domain-containing proteins. Nature. 2006;439(7078):811\u20136.","journal-title":"Nature"},{"issue":"37","key":"2512_CR134","doi-asserted-by":"publisher","first-page":"30984","DOI":"10.1074\/jbc.M112.341040","volume":"287","author":"A Janzer","year":"2012","unstructured":"Janzer A, et al. The H3K4me3 histone demethylase Fbxl10 is a regulator of chemokine expression, cellular morphology, and the metabolome of fibroblasts. J Biol Chem. 2012;287(37):30984\u201392.","journal-title":"J Biol Chem"},{"issue":"7167","key":"2512_CR135","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nature06255","volume":"450","author":"D Frescas","year":"2007","unstructured":"Frescas D, et al. JHDM1B\/FBXL10 is a nucleolar protein that represses transcription of ribosomal RNA genes. Nature. 2007;450(7167):309\u201313.","journal-title":"Nature"},{"issue":"38","key":"2512_CR136","doi-asserted-by":"publisher","first-page":"33061","DOI":"10.1074\/jbc.M111.257667","volume":"286","author":"A Tzatsos","year":"2011","unstructured":"Tzatsos A, et al. Lysine-specific demethylase 2B (KDM2B)-let-7-enhancer of zester homolog 2 (EZH2) pathway regulates cell cycle progression and senescence in primary cells. J Biol Chem. 2011;286(38):33061\u20139.","journal-title":"J Biol Chem"},{"issue":"10","key":"2512_CR137","doi-asserted-by":"publisher","first-page":"5737","DOI":"10.1096\/fj.201800242R","volume":"32","author":"JY Kang","year":"2018","unstructured":"Kang JY, et al. KDM2B is a histone H3K79 demethylase and induces transcriptional repression via sirtuin-1-mediated chromatin silencing. FASEB J. 2018;32(10):5737\u201350.","journal-title":"FASEB J"},{"issue":"3","key":"2512_CR138","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/0008-5472.CAN-11-2575","volume":"72","author":"D Engelmann","year":"2012","unstructured":"Engelmann D, P\u00fctzer BM. The dark side of E2F1: in transit beyond apoptosis. Cancer Res. 2012;72(3):571\u20135.","journal-title":"Cancer Res"},{"issue":"4","key":"2512_CR139","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.molmed.2006.02.002","volume":"12","author":"J Stanelle","year":"2006","unstructured":"Stanelle J, P\u00fctzer BM. E2F1-induced apoptosis: turning killers into therapeutics. Trends Mol Med. 2006;12(4):177\u201385.","journal-title":"Trends Mol Med"},{"issue":"6","key":"2512_CR140","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41568-019-0143-7","volume":"19","author":"LN Kent","year":"2019","unstructured":"Kent LN, Leone G. The broken cycle: E2F dysfunction in cancer. Nat Rev Cancer. 2019;19(6):326\u201338.","journal-title":"Nat Rev Cancer"},{"issue":"7310","key":"2512_CR141","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/nature09303","volume":"466","author":"S Ito","year":"2010","unstructured":"Ito S, et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature. 2010;466(7310):1129\u201333.","journal-title":"Nature"},{"issue":"6047","key":"2512_CR142","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1126\/science.1210597","volume":"333","author":"S Ito","year":"2011","unstructured":"Ito S, et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science. 2011;333(6047):1300\u20133.","journal-title":"Science"},{"issue":"6","key":"2512_CR143","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1083\/jcb.200709044","volume":"179","author":"SS Grewal","year":"2007","unstructured":"Grewal SS, Evans JR, Edgar BA. Drosophila TIF-IA is required for ribosome synthesis and cell growth and is regulated by the TOR pathway. J Cell Biol. 2007;179(6):1105\u201313.","journal-title":"J Cell Biol"},{"issue":"5","key":"2512_CR144","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrc3496","volume":"13","author":"MJ Bywater","year":"2013","unstructured":"Bywater MJ, et al. Dysregulation of the basal RNA polymerase transcription apparatus in cancer. Nat Rev Cancer. 2013;13(5):299\u2013314.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2512_CR145","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41580-022-00573-9","volume":"24","author":"Y Hori","year":"2023","unstructured":"Hori Y, Engel C, Kobayashi T. Regulation of ribosomal RNA gene copy number, transcription and nucleolus organization in eukaryotes. Nat Rev Mol Cell Biol. 2023;24(6):414\u201329.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"24","key":"2512_CR146","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.1128\/MCB.00579-15","volume":"35","author":"Y Tanaka","year":"2015","unstructured":"Tanaka Y, et al. Mild glucose starvation induces KDM2A-mediated H3K36me2 demethylation through AMPK to reduce rRNA transcription and cell proliferation. Mol Cell Biol. 2015;35(24):4170\u201384.","journal-title":"Mol Cell Biol"},{"issue":"7","key":"2512_CR147","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.tcb.2016.04.009","volume":"26","author":"M Entrevan","year":"2016","unstructured":"Entrevan M, Schuettengruber B, Cavalli G. Regulation of genome architecture and function by polycomb proteins. Trends Cell Biol. 2016;26(7):511\u201325.","journal-title":"Trends Cell Biol"},{"issue":"18","key":"2512_CR148","doi-asserted-by":"publisher","first-page":"6880","DOI":"10.1128\/MCB.00630-06","volume":"26","author":"MD Gearhart","year":"2006","unstructured":"Gearhart MD, et al. Polycomb group and SCF ubiquitin ligases are found in a novel BCOR complex that is recruited to BCL6 targets. Mol Cell Biol. 2006;26(18):6880\u20139.","journal-title":"Mol Cell Biol"},{"issue":"5","key":"2512_CR149","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1074\/mcp.M600275-MCP200","volume":"6","author":"C S\u00e1nchez","year":"2007","unstructured":"S\u00e1nchez C, et al. Proteomics analysis of Ring1B\/Rnf2 interactors identifies a novel complex with the Fbxl10\/Jhdm1B histone demethylase and the Bcl6 interacting corepressor. Mol Cell Proteomics. 2007;6(5):820\u201334.","journal-title":"Mol Cell Proteomics"},{"issue":"3","key":"2512_CR150","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.molcel.2012.01.002","volume":"45","author":"Z Gao","year":"2012","unstructured":"Gao Z, et al. PCGF homologs, CBX proteins, and RYBP define functionally distinct PRC1 family complexes. Mol Cell. 2012;45(3):344\u201356.","journal-title":"Mol Cell"},{"issue":"3","key":"2512_CR151","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.cell.2006.03.027","volume":"125","author":"K Yamane","year":"2006","unstructured":"Yamane K, et al. JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell. 2006;125(3):483\u201395.","journal-title":"Cell"},{"issue":"27","key":"2512_CR152","doi-asserted-by":"publisher","first-page":"10606","DOI":"10.1074\/jbc.RA118.001730","volume":"293","author":"K Peng","year":"2018","unstructured":"Peng K, et al. Histone demethylase JMJD1A promotes colorectal cancer growth and metastasis by enhancing Wnt\/\u03b2-catenin signaling. J Biol Chem. 2018;293(27):10606\u201319.","journal-title":"J Biol Chem"},{"issue":"6","key":"2512_CR153","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1053\/j.gastro.2019.08.018","volume":"157","author":"P Dandawate","year":"2019","unstructured":"Dandawate P, et al. The histone demethylase KDM3A, increased in human pancreatic tumors, regulates expression of DCLK1 and promotes tumorigenesis in mice. Gastroenterology. 2019;157(6):1646-1659.e11.","journal-title":"Gastroenterology"},{"key":"2512_CR154","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.70412","author":"W Fang","year":"2021","unstructured":"Fang W, et al. ZHX2 promotes HIF1\u03b1 oncogenic signaling in triple-negative breast cancer. Elife. 2021. https:\/\/doi.org\/10.7554\/eLife.70412.","journal-title":"Elife"},{"issue":"2","key":"2512_CR155","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.canlet.2008.05.029","volume":"272","author":"CD Simpson","year":"2008","unstructured":"Simpson CD, Anyiwe K, Schimmer AD. Anoikis resistance and tumor metastasis. Cancer Lett. 2008;272(2):177\u201385.","journal-title":"Cancer Lett"},{"issue":"3","key":"2512_CR156","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cell.2006.03.028","volume":"125","author":"JR Whetstine","year":"2006","unstructured":"Whetstine JR, et al. Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell. 2006;125(3):467\u201381.","journal-title":"Cell"},{"issue":"7100","key":"2512_CR157","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/nature04853","volume":"442","author":"RJ Klose","year":"2006","unstructured":"Klose RJ, et al. The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature. 2006;442(7100):312\u20136.","journal-title":"Nature"},{"issue":"8","key":"2512_CR158","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nsmb1273","volume":"14","author":"JF Couture","year":"2007","unstructured":"Couture JF, et al. Specificity and mechanism of JMJD2A, a trimethyllysine-specific histone demethylase. Nat Struct Mol Biol. 2007;14(8):689\u201395.","journal-title":"Nat Struct Mol Biol"},{"issue":"13","key":"2512_CR159","doi-asserted-by":"publisher","first-page":"8395","DOI":"10.1074\/jbc.M807818200","volume":"284","author":"P Trojer","year":"2009","unstructured":"Trojer P, et al. Dynamic histone H1 isotype 4 methylation and demethylation by histone lysine methyltransferase G9a\/KMT1C and the Jumonji domain-containing JMJD2\/KDM4 proteins. J Biol Chem. 2009;284(13):8395\u2013405.","journal-title":"J Biol Chem"},{"issue":"7","key":"2512_CR160","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrc2876","volume":"10","author":"P Chi","year":"2010","unstructured":"Chi P, Allis CD, Wang GG. Covalent histone modifications\u2013miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer. 2010;10(7):457\u201369.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2512_CR161","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","volume":"150","author":"MA Dawson","year":"2012","unstructured":"Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12\u201327.","journal-title":"Cell"},{"issue":"6","key":"2512_CR162","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1095\/biolreprod.110.088955","volume":"84","author":"N Iwamori","year":"2011","unstructured":"Iwamori N, et al. The testis-enriched histone demethylase, KDM4D, regulates methylation of histone H3 lysine 9 during spermatogenesis in the mouse but is dispensable for fertility. Biol Reprod. 2011;84(6):1225\u201334.","journal-title":"Biol Reprod"},{"issue":"3","key":"2512_CR163","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1096\/fj.201902584R","volume":"34","author":"DH Lee","year":"2020","unstructured":"Lee DH, et al. Advances in histone demethylase KDM4 as cancer therapeutic targets. FASEB J. 2020;34(3):3461\u201384.","journal-title":"FASEB J"},{"issue":"1","key":"2512_CR164","first-page":"1","volume":"6","author":"RM Labb\u00e9","year":"2013","unstructured":"Labb\u00e9 RM, Holowatyj A, Yang ZQ. Histone lysine demethylase (KDM) subfamily 4: structures, functions and therapeutic potential. Am J Transl Res. 2013;6(1):1\u201315.","journal-title":"Am J Transl Res"},{"issue":"17","key":"2512_CR165","first-page":"4735","volume":"60","author":"ZQ Yang","year":"2000","unstructured":"Yang ZQ, et al. Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines. Cancer Res. 2000;60(17):4735\u20139.","journal-title":"Cancer Res"},{"issue":"20","key":"2512_CR166","doi-asserted-by":"publisher","first-page":"6426","DOI":"10.1158\/1078-0432.CCR-08-0702","volume":"14","author":"U Vinatzer","year":"2008","unstructured":"Vinatzer U, et al. Mucosa-associated lymphoid tissue lymphoma: novel translocations including rearrangements of ODZ2, JMJD2C, and CNN3. Clin Cancer Res. 2008;14(20):6426\u201331.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2512_CR167","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1158\/0008-5472.CAN-12-4300","volume":"73","author":"WL Berry","year":"2013","unstructured":"Berry WL, Janknecht R. KDM4\/JMJD2 histone demethylases: epigenetic regulators in cancer cells. Cancer Res. 2013;73(10):2936\u201342.","journal-title":"Cancer Res"},{"key":"2512_CR168","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002758","author":"WL Yan","year":"2021","unstructured":"Yan WL, et al. Activation of GM-CSF and TLR2 signaling synergistically enhances antigen-specific antitumor immunity and modulates the tumor microenvironment. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-002758.","journal-title":"J Immunother Cancer"},{"key":"2512_CR169","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009541","author":"S Kang","year":"2024","unstructured":"Kang S, et al. Engineered GM-CSF polarizes protumorigenic tumor-associated macrophages to an antitumorigenic phenotype and potently synergizes with IL-12 immunotherapy. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2024-009541.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"2512_CR170","first-page":"1281","volume":"10","author":"R Schreck","year":"1990","unstructured":"Schreck R, Baeuerle PA. NF-kappa B as inducible transcriptional activator of the granulocyte-macrophage colony-stimulating factor gene. Mol Cell Biol. 1990;10(3):1281\u20136.","journal-title":"Mol Cell Biol"},{"issue":"11","key":"2512_CR171","doi-asserted-by":"publisher","first-page":"5547","DOI":"10.1093\/nar\/gky281","volume":"46","author":"KH Hung","year":"2018","unstructured":"Hung KH, et al. The KDM4A\/KDM4C\/NF-\u03baB and WDR5 epigenetic cascade regulates the activation of B cells. Nucleic Acids Res. 2018;46(11):5547\u201360.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"2512_CR172","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.cell.2010.08.011","volume":"142","author":"JS Lee","year":"2010","unstructured":"Lee JS, Smith E, Shilatifard A. The language of histone crosstalk. Cell. 2010;142(5):682\u20135.","journal-title":"Cell"},{"issue":"19","key":"2512_CR173","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1038\/sj.onc.1206380","volume":"22","author":"RZ Luo","year":"2003","unstructured":"Luo RZ, et al. ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene. 2003;22(19):2897\u2013909.","journal-title":"Oncogene"},{"issue":"10 Pt 1","key":"2512_CR174","first-page":"3660","volume":"9","author":"L Wang","year":"2003","unstructured":"Wang L, et al. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. Clin Cancer Res. 2003;9(10 Pt 1):3660\u20136.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2512_CR175","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.3892\/ijo.2012.1618","volume":"41","author":"WL Berry","year":"2012","unstructured":"Berry WL, et al. Oncogenic features of the JMJD2A histone demethylase in breast cancer. Int J Oncol. 2012;41(5):1701\u20136.","journal-title":"Int J Oncol"},{"issue":"1","key":"2512_CR176","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-30-90","volume":"30","author":"BX Li","year":"2011","unstructured":"Li BX, et al. Effects of RNA interference-mediated gene silencing of JMJD2A on human breast cancer cell line MDA-MB-231 in vitro. J Exp Clin Cancer Res. 2011;30(1):90.","journal-title":"J Exp Clin Cancer Res"},{"issue":"22","key":"2512_CR177","first-page":"11623","volume":"47","author":"L Duan","year":"2019","unstructured":"Duan L, et al. Histone lysine demethylase KDM4B regulates the alternative splicing of the androgen receptor in response to androgen deprivation. Nucleic Acids Res. 2019;47(22):11623\u201336.","journal-title":"Nucleic Acids Res"},{"issue":"14","key":"2512_CR178","doi-asserted-by":"publisher","first-page":"5975","DOI":"10.1021\/jm500249n","volume":"57","author":"CH Chu","year":"2014","unstructured":"Chu CH, et al. KDM4B as a target for prostate cancer: structural analysis and selective inhibition by a novel inhibitor. J Med Chem. 2014;57(14):5975\u201385.","journal-title":"J Med Chem"},{"issue":"14","key":"2512_CR179","doi-asserted-by":"publisher","first-page":"6892","DOI":"10.1093\/nar\/gkt469","volume":"41","author":"L Gaughan","year":"2013","unstructured":"Gaughan L, et al. KDM4B is a master regulator of the estrogen receptor signalling cascade. Nucleic Acids Res. 2013;41(14):6892\u2013904.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"2512_CR180","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1084\/jem.20180439","volume":"215","author":"W Wang","year":"2018","unstructured":"Wang W, et al. KDM4B-regulated unfolded protein response as a therapeutic vulnerability in PTEN-deficient breast cancer. J Exp Med. 2018;215(11):2833\u201349.","journal-title":"J Exp Med"},{"issue":"7100","key":"2512_CR181","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nature04837","volume":"442","author":"PA Cloos","year":"2006","unstructured":"Cloos PA, et al. The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature. 2006;442(7100):307\u201311.","journal-title":"Nature"},{"issue":"3","key":"2512_CR182","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03550-w","volume":"12","author":"N Shao","year":"2021","unstructured":"Shao N, et al. GASC1 promotes hepatocellular carcinoma progression by inhibiting the degradation of ROCK2. Cell Death Dis. 2021;12(3):253.","journal-title":"Cell Death Dis"},{"issue":"4","key":"2512_CR183","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/ng.336","volume":"41","author":"PA Northcott","year":"2009","unstructured":"Northcott PA, et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet. 2009;41(4):465\u201372.","journal-title":"Nat Genet"},{"issue":"6","key":"2512_CR184","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.cell.2007.02.003","volume":"128","author":"J Christensen","year":"2007","unstructured":"Christensen J, et al. RBP2 belongs to a family of demethylases, specific for tri-and dimethylated lysine 4 on histone 3. Cell. 2007;128(6):1063\u201376.","journal-title":"Cell"},{"issue":"10","key":"2512_CR185","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1101\/gad.470008","volume":"22","author":"D Pasini","year":"2008","unstructured":"Pasini D, et al. Coordinated regulation of transcriptional repression by the RBP2 H3K4 demethylase and Polycomb-repressive complex 2. Genes Dev. 2008;22(10):1345\u201355.","journal-title":"Genes Dev"},{"issue":"39","key":"2512_CR186","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2305092120","volume":"120","author":"D Han","year":"2023","unstructured":"Han D, et al. BRWD3 promotes KDM5 degradation to maintain H3K4 methylation levels. Proc Natl Acad Sci U S A. 2023;120(39):e2305092120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2512_CR187","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1093\/cvr\/cvae014","volume":"120","author":"M Deogharia","year":"2024","unstructured":"Deogharia M, et al. Histone demethylase KDM5 regulates cardiomyocyte maturation by promoting fatty acid oxidation, oxidative phosphorylation, and myofibrillar organization. Cardiovasc Res. 2024;120(6):630\u201343.","journal-title":"Cardiovasc Res"},{"issue":"2","key":"2512_CR188","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.celrep.2013.12.021","volume":"6","author":"BJ Klein","year":"2014","unstructured":"Klein BJ, et al. The histone-H3K4-specific demethylase KDM5B binds to its substrate and product through distinct PHD fingers. Cell Rep. 2014;6(2):325\u201335.","journal-title":"Cell Rep"},{"issue":"6332","key":"2512_CR189","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/352251a0","volume":"352","author":"D Defeo-Jones","year":"1991","unstructured":"Defeo-Jones D, et al. Cloning of cDNAs for cellular proteins that bind to the retinoblastoma gene product. Nature. 1991;352(6332):251\u20134.","journal-title":"Nature"},{"issue":"15","key":"2512_CR190","doi-asserted-by":"publisher","first-page":"4711","DOI":"10.1158\/0008-5472.CAN-12-3165","volume":"73","author":"YC Teng","year":"2013","unstructured":"Teng YC, et al. Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis. Cancer Res. 2013;73(15):4711\u201321.","journal-title":"Cancer Res"},{"key":"2512_CR191","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-81","volume":"13","author":"L Li","year":"2014","unstructured":"Li L, et al. Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis. Mol Cancer. 2014;13:81.","journal-title":"Mol Cancer"},{"issue":"5","key":"2512_CR192","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nrc3720","volume":"14","author":"RC Baxter","year":"2014","unstructured":"Baxter RC. IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer. 2014;14(5):329\u201341.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"2512_CR193","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.7150\/thno.53225","volume":"11","author":"S Mustafi","year":"2021","unstructured":"Mustafi S, et al. Vitamin C sensitizes triple negative breast cancer to PI3K inhibition therapy. Theranostics. 2021;11(8):3552\u201364.","journal-title":"Theranostics"},{"issue":"22","key":"2512_CR194","doi-asserted-by":"publisher","first-page":"15633","DOI":"10.1074\/jbc.274.22.15633","volume":"274","author":"PJ Lu","year":"1999","unstructured":"Lu PJ, et al. A novel gene (PLU-1) containing highly conserved putative DNA\/chromatin binding motifs is specifically up-regulated in breast cancer. J Biol Chem. 1999;274(22):15633\u201345.","journal-title":"J Biol Chem"},{"issue":"25","key":"2512_CR195","doi-asserted-by":"publisher","first-page":"17620","DOI":"10.1074\/jbc.M114.570853","volume":"289","author":"MR Zou","year":"2014","unstructured":"Zou MR, et al. Histone demethylase jumonji AT-rich interactive domain 1B (JARID1B) controls mammary gland development by regulating key developmental and lineage specification genes. J Biol Chem. 2014;289(25):17620\u201333.","journal-title":"J Biol Chem"},{"issue":"1","key":"2512_CR196","doi-asserted-by":"publisher","DOI":"10.1186\/s13062-024-00573-z","volume":"19","author":"S Chen","year":"2024","unstructured":"Chen S, et al. USP44 regulates HEXIM1 stability to inhibit tumorigenesis and metastasis of oral squamous cell carcinoma. Biol Direct. 2024;19(1):143.","journal-title":"Biol Direct"},{"issue":"47","key":"2512_CR197","doi-asserted-by":"publisher","first-page":"40531","DOI":"10.1074\/jbc.M111.304865","volume":"286","author":"D Mitra","year":"2011","unstructured":"Mitra D, et al. Jumonji\/ARID1 B (JARID1B) protein promotes breast tumor cell cycle progression through epigenetic repression of microRNA let-7e. J Biol Chem. 2011;286(47):40531\u20135.","journal-title":"J Biol Chem"},{"issue":"5","key":"2512_CR198","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.molcel.2014.01.029","volume":"53","author":"E Vir\u00e9","year":"2014","unstructured":"Vir\u00e9 E, et al. The breast cancer oncogene EMSY represses transcription of antimetastatic microRNA miR-31. Mol Cell. 2014;53(5):806\u201318.","journal-title":"Mol Cell"},{"issue":"6","key":"2512_CR199","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/hmg\/3.6.879","volume":"3","author":"AI Agulnik","year":"1994","unstructured":"Agulnik AI, et al. A novel X gene with a widely transcribed Y-linked homologue escapes X-inactivation in mouse and human. Hum Mol Genet. 1994;3(6):879\u201384.","journal-title":"Hum Mol Genet"},{"issue":"5","key":"2512_CR200","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.molcel.2013.01.038","volume":"49","author":"E Calo","year":"2013","unstructured":"Calo E, Wysocka J. Modification of enhancer chromatin: what, how, and why? Mol Cell. 2013;49(5):825\u201337.","journal-title":"Mol Cell"},{"issue":"9","key":"2512_CR201","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.molcel.2024.02.030","volume":"84","author":"N Kubo","year":"2024","unstructured":"Kubo N, et al. H3K4me1 facilitates promoter-enhancer interactions and gene activation during embryonic stem cell differentiation. Mol Cell. 2024;84(9):1742-1752.e5.","journal-title":"Mol Cell"},{"issue":"2","key":"2512_CR202","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.cell.2016.02.064","volume":"165","author":"H Shen","year":"2016","unstructured":"Shen H, et al. Suppression of enhancer overactivation by a RACK7-histone demethylase complex. Cell. 2016;165(2):331\u201342.","journal-title":"Cell"},{"issue":"6","key":"2512_CR203","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1158\/0008-5472.CAN-17-2118","volume":"78","author":"X Chen","year":"2018","unstructured":"Chen X, et al. E6 protein expressed by high-risk HPV activates super-enhancers of the EGFR and c-MET oncogenes by destabilizing the histone demethylase KDM5C. Cancer Res. 2018;78(6):1418\u201330.","journal-title":"Cancer Res"},{"issue":"2","key":"2512_CR204","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.tcb.2024.06.001","volume":"35","author":"H Wang","year":"2025","unstructured":"Wang H, Helin K. Roles of H3K4 methylation in biology and disease. Trends Cell Biol. 2025;35(2):115\u201328.","journal-title":"Trends Cell Biol"},{"issue":"10","key":"2512_CR205","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s003350010174","volume":"11","author":"SC Fossey","year":"2000","unstructured":"Fossey SC, et al. Identification and characterization of PRKCBP1, a candidate RACK-like protein. Mamm Genome. 2000;11(10):919\u201325.","journal-title":"Mamm Genome"},{"key":"2512_CR206","doi-asserted-by":"publisher","DOI":"10.1172\/JCI171166","author":"M Luo","year":"2024","unstructured":"Luo M, et al. ZMYND8 protects breast cancer stem cells against oxidative stress and ferroptosis through activation of NRF2. J Clin Invest. 2024. https:\/\/doi.org\/10.1172\/JCI171166.","journal-title":"J Clin Invest"},{"issue":"13","key":"2512_CR207","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1016\/j.molcel.2021.04.009","volume":"81","author":"Q Pan","year":"2021","unstructured":"Pan Q, et al. The ZMYND8-regulated mevalonate pathway endows YAP-high intestinal cancer with metabolic vulnerability. Mol Cell. 2021;81(13):2736-2751.e8.","journal-title":"Mol Cell"},{"issue":"4","key":"2512_CR208","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1158\/0008-5472.CAN-15-0906","volume":"76","author":"N Li","year":"2016","unstructured":"Li N, et al. JARID1D is a suppressor and prognostic marker of prostate cancer invasion and metastasis. Cancer Res. 2016;76(4):831\u201343.","journal-title":"Cancer Res"},{"issue":"22","key":"2512_CR209","doi-asserted-by":"publisher","first-page":"6259","DOI":"10.1073\/pnas.1600420113","volume":"113","author":"K Komura","year":"2016","unstructured":"Komura K, et al. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. Proc Natl Acad Sci U S A. 2016;113(22):6259\u201364.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"50","key":"2512_CR210","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2402022121","volume":"121","author":"J Chen","year":"2024","unstructured":"Chen J, et al. KDM5D histone demethylase mediates p38\u03b1 inactivation via its enzymatic activity to inhibit cancer progression. Proc Natl Acad Sci USA. 2024;121(50):e2402022121.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"47","key":"2512_CR211","doi-asserted-by":"publisher","first-page":"18439","DOI":"10.1073\/pnas.0707292104","volume":"104","author":"S Hong","year":"2007","unstructured":"Hong S, et al. Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases. Proc Natl Acad Sci U S A. 2007;104(47):18439\u201344.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2512_CR212","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nrg1945","volume":"7","author":"RJ Klose","year":"2006","unstructured":"Klose RJ, Kallin EM, Zhang Y. JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet. 2006;7(9):715\u201327.","journal-title":"Nat Rev Genet"},{"issue":"26","key":"2512_CR213","doi-asserted-by":"publisher","first-page":"18302","DOI":"10.1074\/jbc.M114.555052","volume":"289","author":"LJ Walport","year":"2014","unstructured":"Walport LJ, et al. Human UTY(KDM6C) is a male-specific N\u03f5-methyl lysyl demethylase. J Biol Chem. 2014;289(26):18302\u201313.","journal-title":"J Biol Chem"},{"issue":"7163","key":"2512_CR214","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nature06145","volume":"449","author":"K Agger","year":"2007","unstructured":"Agger K, et al. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature. 2007;449(7163):731\u20134.","journal-title":"Nature"},{"issue":"5","key":"2512_CR215","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/ng.349","volume":"41","author":"G van Haaften","year":"2009","unstructured":"van Haaften G, et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet. 2009;41(5):521\u20133.","journal-title":"Nat Genet"},{"issue":"2","key":"2512_CR216","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ccell.2019.01.001","volume":"35","author":"L Wang","year":"2019","unstructured":"Wang L, Shilatifard A. UTX mutations in human cancer. Cancer Cell. 2019;35(2):168\u201376.","journal-title":"Cancer Cell"},{"issue":"1","key":"2512_CR217","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06616-0","volume":"9","author":"JJ Pitt","year":"2018","unstructured":"Pitt JJ, et al. Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. Nat Commun. 2018;9(1):4181.","journal-title":"Nat Commun"},{"issue":"23","key":"2512_CR218","doi-asserted-by":"publisher","first-page":"4745","DOI":"10.1128\/MCB.01181-13","volume":"33","author":"D Hu","year":"2013","unstructured":"Hu D, et al. The MLL3\/MLL4 branches of the COMPASS family function as major histone H3K4 monomethylases at enhancers. Mol Cell Biol. 2013;33(23):4745\u201354.","journal-title":"Mol Cell Biol"},{"issue":"6","key":"2512_CR219","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.molcel.2014.02.033","volume":"53","author":"HM Herz","year":"2014","unstructured":"Herz HM, Hu D, Shilatifard A. Enhancer malfunction in cancer. Mol Cell. 2014;53(6):859\u201366.","journal-title":"Mol Cell"},{"key":"2512_CR220","doi-asserted-by":"publisher","DOI":"10.1172\/JCI169993","author":"Z Zhao","year":"2023","unstructured":"Zhao Z, et al. Therapeutic targeting of metabolic vulnerabilities in cancers with MLL3\/4-COMPASS epigenetic regulator mutations. J Clin Invest. 2023. https:\/\/doi.org\/10.1172\/JCI169993.","journal-title":"J Clin Invest"},{"issue":"16","key":"2512_CR221","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1038\/s41388-020-1218-3","volume":"39","author":"H Kato","year":"2020","unstructured":"Kato H, et al. Cancer-derived UTX TPR mutations G137V and D336G impair interaction with MLL3\/4 complexes and affect UTX subcellular localization. Oncogene. 2020;39(16):3322\u201335.","journal-title":"Oncogene"},{"issue":"4","key":"2512_CR222","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nsmb.1778","volume":"17","author":"W Feng","year":"2010","unstructured":"Feng W, et al. PHF8 activates transcription of rRNA genes through H3K4me3 binding and H3K9me1\/2 demethylation. Nat Struct Mol Biol. 2010;17(4):445\u201350.","journal-title":"Nat Struct Mol Biol"},{"issue":"13","key":"2512_CR223","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1128\/MCB.01520-09","volume":"30","author":"K Fortschegger","year":"2010","unstructured":"Fortschegger K, et al. PHF8 targets histone methylation and RNA polymerase II to activate transcription. Mol Cell Biol. 2010;30(13):3286\u201398.","journal-title":"Mol Cell Biol"},{"issue":"7305","key":"2512_CR224","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/nature09272","volume":"466","author":"W Liu","year":"2010","unstructured":"Liu W, et al. PHF8 mediates histone H4 lysine 20 demethylation events involved in cell cycle progression. Nature. 2010;466(7305):508\u201312.","journal-title":"Nature"},{"issue":"13","key":"2512_CR225","doi-asserted-by":"publisher","first-page":"9322","DOI":"10.1074\/jbc.C109.097667","volume":"285","author":"H Wen","year":"2010","unstructured":"Wen H, et al. Recognition of histone H3K4 trimethylation by the plant homeodomain of PHF2 modulates histone demethylation. J Biol Chem. 2010;285(13):9322\u20136.","journal-title":"J Biol Chem"},{"issue":"6","key":"2512_CR226","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ncb2228","volume":"13","author":"A Baba","year":"2011","unstructured":"Baba A, et al. PKA-dependent regulation of the histone lysine demethylase complex PHF2-ARID5B. Nat Cell Biol. 2011;13(6):668\u201375.","journal-title":"Nat Cell Biol"},{"issue":"6277","key":"2512_CR227","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad3680","volume":"351","author":"DR Pattabiraman","year":"2016","unstructured":"Pattabiraman DR, et al. Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability. Science. 2016;351(6277):aad3680.","journal-title":"Science"},{"issue":"1","key":"2512_CR228","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.molcel.2012.07.020","volume":"48","author":"JD Stender","year":"2012","unstructured":"Stender JD, et al. Control of proinflammatory gene programs by regulated trimethylation and demethylation of histone H4K20. Mol Cell. 2012;48(1):28\u201338.","journal-title":"Mol Cell"},{"issue":"29","key":"2512_CR229","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1038\/onc.2011.512","volume":"31","author":"M Bj\u00f6rkman","year":"2012","unstructured":"Bj\u00f6rkman M, et al. Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion. Oncogene. 2012;31(29):3444\u201356.","journal-title":"Oncogene"},{"issue":"1","key":"2512_CR230","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-018-0890-4","volume":"37","author":"W Zhou","year":"2018","unstructured":"Zhou W, et al. PHF8 upregulation contributes to autophagic degradation of E-cadherin, epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2018;37(1):215.","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"2512_CR231","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.bbagrm.2017.07.005","volume":"1860","author":"PK Maina","year":"2017","unstructured":"Maina PK, et al. Histone demethylase PHF8 regulates hypoxia signaling through HIF1\u03b1 and H3K4me3. Biochimica et Biophysica Acta (BBA). 2017;1860(9):1002\u201312.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"2512_CR232","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-7-84","volume":"7","author":"S Sinha","year":"2008","unstructured":"Sinha S, et al. Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: pathological significance in early- and late-onset breast carcinoma. Mol Cancer. 2008;7:84.","journal-title":"Mol Cancer"},{"issue":"1","key":"2512_CR233","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrm3915","volume":"16","author":"KK Biggar","year":"2015","unstructured":"Biggar KK, Li SS. Non-histone protein methylation as a regulator of cellular signalling and function. Nat Rev Mol Cell Biol. 2015;16(1):5\u201317.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7119","key":"2512_CR234","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/nature05287","volume":"444","author":"J Huang","year":"2006","unstructured":"Huang J, et al. Repression of p53 activity by Smyd2-mediated methylation. Nature. 2006;444(7119):629\u201332.","journal-title":"Nature"},{"issue":"7015","key":"2512_CR235","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nature03117","volume":"432","author":"S Chuikov","year":"2004","unstructured":"Chuikov S, et al. Regulation of p53 activity through lysine methylation. Nature. 2004;432(7015):353\u201360.","journal-title":"Nature"},{"issue":"7158","key":"2512_CR236","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nature06092","volume":"449","author":"J Huang","year":"2007","unstructured":"Huang J, et al. P53 is regulated by the lysine demethylase LSD1. Nature. 2007;449(7158):105\u20138.","journal-title":"Nature"},{"issue":"5241","key":"2512_CR237","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1126\/science.270.5241.1491","volume":"270","author":"S Kato","year":"1995","unstructured":"Kato S, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 1995;270(5241):1491\u20134.","journal-title":"Science"},{"key":"2512_CR238","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf7684","author":"S Ma","year":"2021","unstructured":"Ma S, et al. PHF8-promoted TOPBP1 demethylation drives ATR activation and preserves genome stability. Sci Adv. 2021. https:\/\/doi.org\/10.1126\/sciadv.abf7684.","journal-title":"Sci Adv"},{"key":"2512_CR239","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.canlet.2022.01.010","volume":"530","author":"S Ma","year":"2022","unstructured":"Ma S, et al. Disrupting PHF8-TOPBP1 connection elicits a breast tumor-specific vulnerability to chemotherapeutics. Cancer Lett. 2022;530:29\u201344.","journal-title":"Cancer Lett"},{"issue":"10","key":"2512_CR240","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1016\/j.celrep.2015.11.007","volume":"13","author":"X Liu","year":"2015","unstructured":"Liu X, Secombe J. The histone demethylase KDM5 activates gene expression by recognizing chromatin context through its PHD reader motif. Cell Rep. 2015;13(10):2219\u201331.","journal-title":"Cell Rep"},{"issue":"5","key":"2512_CR241","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.celrep.2014.02.004","volume":"6","author":"J Cao","year":"2014","unstructured":"Cao J, et al. Histone demethylase RBP2 is critical for breast cancer progression and metastasis. Cell Rep. 2014;6(5):868\u201377.","journal-title":"Cell Rep"},{"issue":"3","key":"2512_CR242","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.stem.2012.01.017","volume":"10","author":"SC Boutet","year":"2012","unstructured":"Boutet SC, et al. Alternative polyadenylation mediates microRNA regulation of muscle stem cell function. Cell Stem Cell. 2012;10(3):327\u201336.","journal-title":"Cell Stem Cell"},{"issue":"11","key":"2512_CR243","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1501662","volume":"2","author":"LP Blair","year":"2016","unstructured":"Blair LP, et al. KDM5 lysine demethylases are involved in maintenance of 3\u2019UTR length. Sci Adv. 2016;2(11):e1501662.","journal-title":"Sci Adv"},{"issue":"12","key":"2512_CR244","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1128\/MCB.06392-11","volume":"32","author":"F Tie","year":"2012","unstructured":"Tie F, et al. Histone demethylase UTX and chromatin remodeler BRM bind directly to CBP and modulate acetylation of histone H3 lysine 27. Mol Cell Biol. 2012;32(12):2323\u201334.","journal-title":"Mol Cell Biol"},{"issue":"2","key":"2512_CR245","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.molcel.2017.06.028","volume":"67","author":"SP Wang","year":"2017","unstructured":"Wang SP, et al. A UTX-MLL4-p300 transcriptional regulatory network coordinately shapes active enhancer landscapes for eliciting transcription. Mol Cell. 2017;67(2):308-321.e6.","journal-title":"Mol Cell"},{"issue":"38","key":"2512_CR246","doi-asserted-by":"publisher","first-page":"15324","DOI":"10.1073\/pnas.1204166109","volume":"109","author":"C Wang","year":"2012","unstructured":"Wang C, et al. UTX regulates mesoderm differentiation of embryonic stem cells independent of H3K27 demethylase activity. Proc Natl Acad Sci U S A. 2012;109(38):15324\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"2512_CR247","doi-asserted-by":"publisher","first-page":"21918","DOI":"10.18632\/oncotarget.15747","volume":"8","author":"J Xun","year":"2017","unstructured":"Xun J, et al. JMJD3 suppresses stem cell-like characteristics in breast cancer cells by downregulation of Oct4 independently of its demethylase activity. Oncotarget. 2017;8(13):21918\u201329.","journal-title":"Oncotarget"},{"issue":"1","key":"2512_CR248","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35795-8","volume":"14","author":"JM Lee","year":"2023","unstructured":"Lee JM, et al. Control of protein stability by post-translational modifications. Nat Commun. 2023;14(1):201.","journal-title":"Nat Commun"},{"issue":"11","key":"2512_CR249","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/j.ccell.2024.09.006","volume":"42","author":"H Li","year":"2024","unstructured":"Li H, et al. Lactylation in cancer: current understanding and challenges. Cancer Cell. 2024;42(11):1803\u20137.","journal-title":"Cancer Cell"},{"issue":"1","key":"2512_CR250","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-024-00624-3","volume":"29","author":"B Wei","year":"2024","unstructured":"Wei B, et al. Crosstalk between SUMOylation and other post-translational modifications in breast cancer. Cell Mol Biol Lett. 2024;29(1):107.","journal-title":"Cell Mol Biol Lett"},{"issue":"12","key":"2512_CR251","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.tplants.2018.09.004","volume":"23","author":"LD Vu","year":"2018","unstructured":"Vu LD, Gevaert K, De Smet I. Protein language: post-translational modifications talking to each other. Trends Plant Sci. 2018;23(12):1068\u201380.","journal-title":"Trends Plant Sci"},{"issue":"1","key":"2512_CR252","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01300-8","volume":"8","author":"F Shu","year":"2023","unstructured":"Shu F, et al. Epigenetic and post-translational modifications in autophagy: biological functions and therapeutic targets. Signal Transduct Target Ther. 2023;8(1):32.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"2512_CR253","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.tibs.2023.12.004","volume":"49","author":"NM Karakatsanis","year":"2024","unstructured":"Karakatsanis NM, Hamey JJ, Wilkins MR. Taking me away: the function of phosphorylation on histone lysine demethylases. Trends Biochem Sci. 2024;49(3):257\u201376.","journal-title":"Trends Biochem Sci"},{"issue":"2","key":"2512_CR254","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel DP. Micrornas: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281\u201397.","journal-title":"Cell"},{"issue":"3","key":"2512_CR255","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/emmm.201100209","volume":"4","author":"MV Iorio","year":"2012","unstructured":"Iorio MV, Croce CM. Microrna dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 2012;4(3):143\u201359.","journal-title":"EMBO Mol Med"},{"issue":"9","key":"2512_CR256","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111294","volume":"40","author":"TL Shao","year":"2022","unstructured":"Shao TL, Ting RT, Lee MC. Identification of Lsd1-interacting non-coding RNAs as regulators of fly oogenesis. Cell Rep. 2022;40(9):111294.","journal-title":"Cell Rep"},{"issue":"2","key":"2512_CR257","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","volume":"23","author":"FJ Groelly","year":"2023","unstructured":"Groelly FJ, et al. Targeting DNA damage response pathways in cancer. Nat Rev Cancer. 2023;23(2):78\u201394.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2512_CR258","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1001\/jamaoncol.2023.7322","volume":"10","author":"S Morganti","year":"2024","unstructured":"Morganti S, et al. PARP inhibitors for breast cancer treatment: a review. JAMA Oncol. 2024;10(5):658\u201370.","journal-title":"JAMA Oncol"},{"issue":"8","key":"2512_CR259","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1038\/emboj.2012.47","volume":"31","author":"FA Mallette","year":"2012","unstructured":"Mallette FA, et al. RNF8- and RNF168-dependent degradation of KDM4A\/JMJD2A triggers 53BP1 recruitment to DNA damage sites. EMBO J. 2012;31(8):1865\u201378.","journal-title":"EMBO J"},{"issue":"1","key":"2512_CR260","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1158\/0008-5472.CAN-18-1310","volume":"79","author":"Y Xiang","year":"2019","unstructured":"Xiang Y, et al. Histone demethylase KDM4B promotes DNA damage by activating long interspersed nuclear element-1. Cancer Res. 2019;79(1):86\u201398.","journal-title":"Cancer Res"},{"issue":"1","key":"2512_CR261","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-024-01901-x","volume":"26","author":"W Wu","year":"2024","unstructured":"Wu W, et al. Ribosomal S6 kinase (RSK) plays a critical role in DNA damage response via the phosphorylation of histone lysine demethylase KDM4B. Breast Cancer Res. 2024;26(1):146.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"2512_CR262","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02080-z","volume":"10","author":"I Pellarin","year":"2025","unstructured":"Pellarin I, et al. Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduct Target Ther. 2025;10(1):11.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2512_CR263","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56674-4","volume":"16","author":"V Kumarasamy","year":"2025","unstructured":"Kumarasamy V, et al. Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle. Nat Commun. 2025;16(1):1476.","journal-title":"Nat Commun"},{"issue":"2","key":"2512_CR264","doi-asserted-by":"publisher","first-page":"5417","DOI":"10.4238\/2015.May.22.11","volume":"14","author":"LH Zhao","year":"2015","unstructured":"Zhao LH, Liu HG. Immunohistochemical detection and clinicopathological significance of JARID1B\/KDM5B and P16 expression in invasive ductal carcinoma of the breast. Genet Mol Res. 2015;14(2):5417\u201326.","journal-title":"Genet Mol Res"},{"issue":"1","key":"2512_CR265","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/path.2430","volume":"217","author":"JM Gee","year":"2009","unstructured":"Gee JM, et al. Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival. J Pathol. 2009;217(1):32\u201341.","journal-title":"J Pathol"},{"issue":"18","key":"2512_CR266","doi-asserted-by":"publisher","first-page":"17617","DOI":"10.1074\/jbc.M502278200","volume":"280","author":"S Mukherjee","year":"2005","unstructured":"Mukherjee S, Conrad SE. C-Myc suppresses p21WAF1\/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells. J Biol Chem. 2005;280(18):17617\u201325.","journal-title":"J Biol Chem"},{"issue":"4","key":"2512_CR267","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13338","volume":"20","author":"M Ogrodnik","year":"2021","unstructured":"Ogrodnik M. Cellular aging beyond cellular senescence: markers of senescence prior to cell cycle arrest in vitro and in vivo. Aging Cell. 2021;20(4):e13338.","journal-title":"Aging Cell"},{"issue":"6","key":"2512_CR268","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41568-022-00450-9","volume":"22","author":"L Wang","year":"2022","unstructured":"Wang L, Lankhorst L, Bernards R. Exploiting senescence for the treatment of cancer. Nat Rev Cancer. 2022;22(6):340\u201355.","journal-title":"Nat Rev Cancer"},{"issue":"17","key":"2512_CR269","doi-asserted-by":"publisher","first-page":"4770","DOI":"10.1016\/j.cell.2024.06.019","volume":"187","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, et al. A non-canonical role for a small nucleolar RNA in ribosome biogenesis and senescence. Cell. 2024;187(17):4770-4789.e23.","journal-title":"Cell"},{"issue":"2","key":"2512_CR270","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/s41416-020-01112-z","volume":"124","author":"JY Chen","year":"2021","unstructured":"Chen JY, et al. Lysine demethylase 2A expression in cancer-associated fibroblasts promotes breast tumour growth. Br J Cancer. 2021;124(2):484\u201393.","journal-title":"Br J Cancer"},{"key":"2512_CR271","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10574","volume":"7","author":"Y Johmura","year":"2016","unstructured":"Johmura Y, et al. SCF(Fbxo22)-KDM4A targets methylated p53 for degradation and regulates senescence. Nat Commun. 2016;7:10574.","journal-title":"Nat Commun"},{"issue":"4","key":"2512_CR272","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12772","volume":"17","author":"E Cuy\u00e0s","year":"2018","unstructured":"Cuy\u00e0s E, et al. Metformin directly targets the H3K27me3 demethylase KDM6A\/UTX. Aging Cell. 2018;17(4):e12772.","journal-title":"Aging Cell"},{"issue":"1","key":"2512_CR273","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44348-y","volume":"15","author":"R Pallavi","year":"2024","unstructured":"Pallavi R, et al. Caloric restriction leads to druggable LSD1-dependent cancer stem cells expansion. Nat Commun. 2024;15(1):828.","journal-title":"Nat Commun"},{"issue":"5","key":"2512_CR274","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1158\/2159-8290.CD-15-0011","volume":"5","author":"AN Hata","year":"2015","unstructured":"Hata AN, Engelman JA, Faber AC. The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics. Cancer Discov. 2015;5(5):475\u201387.","journal-title":"Cancer Discov"},{"issue":"10","key":"2512_CR275","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","volume":"14","author":"T Shibue","year":"2017","unstructured":"Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14(10):611\u201329.","journal-title":"Nat Rev Clin Oncol"},{"key":"2512_CR276","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-pathol-012615-044438","volume":"11","author":"D Nassar","year":"2016","unstructured":"Nassar D, Blanpain C. Cancer stem cells: basic concepts and therapeutic implications. Annu Rev Pathol. 2016;11:47\u201376.","journal-title":"Annu Rev Pathol"},{"key":"2512_CR277","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ctrv.2018.07.004","volume":"69","author":"X Bai","year":"2018","unstructured":"Bai X, et al. Cancer stem cell in breast cancer therapeutic resistance. Cancer Treat Rev. 2018;69:152\u201363.","journal-title":"Cancer Treat Rev"},{"key":"2512_CR278","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116549","volume":"229","author":"Y Tong","year":"2024","unstructured":"Tong Y, et al. LSD1 is a promising target to treat cancers by modulating cell stemness. Biochem Pharmacol. 2024;229:116549.","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"2512_CR279","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1093\/procel\/pwad009","volume":"14","author":"X Dou","year":"2023","unstructured":"Dou X, et al. METTL14 is a chromatin regulator independent of its RNA N6-methyladenosine methyltransferase activity. Protein Cell. 2023;14(9):683\u201397.","journal-title":"Protein Cell"},{"key":"2512_CR280","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.580036","volume":"11","author":"S Wang","year":"2020","unstructured":"Wang S, et al. Effect of N6-Methyladenosine Regulators on Progression and Prognosis of Triple-Negative Breast Cancer. Front Genet. 2020;11:580036.","journal-title":"Front Genet"},{"issue":"11","key":"2512_CR281","doi-asserted-by":"publisher","first-page":"6196","DOI":"10.1093\/nar\/gkab413","volume":"49","author":"S Nabeel-Shah","year":"2021","unstructured":"Nabeel-Shah S, et al. Functional characterization of RebL1 highlights the evolutionary conservation of oncogenic activities of the RBBP4\/7 orthologue in Tetrahymena thermophila. Nucleic Acids Res. 2021;49(11):6196\u2013212.","journal-title":"Nucleic Acids Res"},{"issue":"20","key":"2512_CR282","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1101\/gad.1588207","volume":"21","author":"YH Loh","year":"2007","unstructured":"Loh YH, et al. Jmjd1a and Jmjd2c histone H3 lys 9 demethylases regulate self-renewal in embryonic stem cells. Genes Dev. 2007;21(20):2545\u201357.","journal-title":"Genes Dev"},{"issue":"4","key":"2512_CR283","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s11010-023-04777-1","volume":"479","author":"XY Wang","year":"2024","unstructured":"Wang XY, et al. KDM4B down-regulation facilitated breast cancer cell stemness via PHGDH upregulation in H3K36me3-dependent manner. Mol Cell Biochem. 2024;479(4):915\u201328.","journal-title":"Mol Cell Biochem"},{"issue":"11","key":"2512_CR284","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/onc.2016.320","volume":"36","author":"S Ramadoss","year":"2017","unstructured":"Ramadoss S, et al. Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance. Oncogene. 2017;36(11):1537\u201345.","journal-title":"Oncogene"},{"issue":"1","key":"2512_CR285","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2020.1788900","volume":"12","author":"QQ Liu","year":"2020","unstructured":"Liu QQ, et al. Enterotoxigenic Bacteroides fragilis induces the stemness in colorectal cancer via upregulating histone demethylase JMJD2B. Gut Microbes. 2020;12(1):1788900.","journal-title":"Gut Microbes"},{"issue":"1","key":"2512_CR286","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00674-5","volume":"6","author":"T Lang","year":"2021","unstructured":"Lang T, et al. Disruption of KDM4C-ALDH1A3 feed-forward loop inhibits stemness, tumorigenesis and chemoresistance of gastric cancer stem cells. Signal Transduct Target Ther. 2021;6(1):336.","journal-title":"Signal Transduct Target Ther"},{"key":"2512_CR287","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw5473","author":"B Faubert","year":"2020","unstructured":"Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020. https:\/\/doi.org\/10.1126\/science.aaw5473.","journal-title":"Science"},{"issue":"1","key":"2512_CR288","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01316-8","volume":"20","author":"L Xia","year":"2021","unstructured":"Xia L, et al. The cancer metabolic reprogramming and immune response. Mol Cancer. 2021;20(1):28.","journal-title":"Mol Cancer"},{"issue":"1","key":"2512_CR289","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02165-x","volume":"23","author":"S Liu","year":"2024","unstructured":"Liu S, et al. Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer. Mol Cancer. 2024;23(1):261.","journal-title":"Mol Cancer"},{"issue":"11","key":"2512_CR290","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/cac2.12374","volume":"42","author":"T Ge","year":"2022","unstructured":"Ge T, et al. Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities. Cancer Commun. 2022;42(11):1049\u201382.","journal-title":"Cancer Commun"},{"issue":"1","key":"2512_CR291","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01498-2","volume":"16","author":"HR Jin","year":"2023","unstructured":"Jin HR, et al. Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics. J Hematol Oncol. 2023;16(1):103.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"2512_CR292","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/j.cmet.2022.09.023","volume":"34","author":"M Martin-Perez","year":"2022","unstructured":"Martin-Perez M, et al. The role of lipids in cancer progression and metastasis. Cell Metab. 2022;34(11):1675\u201399.","journal-title":"Cell Metab"},{"issue":"1","key":"2512_CR293","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56458-w","volume":"16","author":"XQ Song","year":"2025","unstructured":"Song XQ, et al. Copy number amplification of FLAD1 promotes the progression of triple-negative breast cancer through lipid metabolism. Nat Commun. 2025;16(1):1241.","journal-title":"Nat Commun"},{"key":"2512_CR294","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217493","volume":"612","author":"X You","year":"2025","unstructured":"You X, et al. Dual targeting PPAR\u03b1 and NPC1L1 metabolic vulnerabilities blocks tumorigenesis. Cancer Lett. 2025;612:217493.","journal-title":"Cancer Lett"},{"issue":"4","key":"2512_CR295","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s12276-023-00971-9","volume":"55","author":"J Jin","year":"2023","unstructured":"Jin J, et al. Targeting glutamine metabolism as a therapeutic strategy for cancer. Exp Mol Med. 2023;55(4):706\u201315.","journal-title":"Exp Mol Med"},{"key":"2512_CR296","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1146\/annurev-bioeng-071516-044546","volume":"19","author":"L Yang","year":"2017","unstructured":"Yang L, Venneti S, Nagrath D. Glutaminolysis: a hallmark of cancer metabolism. Annu Rev Biomed Eng. 2017;19:163\u201394.","journal-title":"Annu Rev Biomed Eng"},{"issue":"2","key":"2512_CR297","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021110306","volume":"41","author":"J Shao","year":"2022","unstructured":"Shao J, et al. Cytosolic GDH1 degradation restricts protein synthesis to sustain tumor cell survival following amino acid deprivation. EMBO J. 2022;41(2):e110306.","journal-title":"EMBO J"},{"issue":"1","key":"2512_CR298","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55768-9","volume":"16","author":"Y Yi","year":"2025","unstructured":"Yi Y, et al. Mitochondrial-cytochrome c oxidase II promotes glutaminolysis to sustain tumor cell survival upon glucose deprivation. Nat Commun. 2025;16(1):212.","journal-title":"Nat Commun"},{"issue":"3","key":"2512_CR299","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.celrep.2015.12.053","volume":"14","author":"E Zhao","year":"2016","unstructured":"Zhao E, et al. KDM4C and ATF4 cooperate in transcriptional control of amino acid metabolism. Cell Rep. 2016;14(3):506\u201319.","journal-title":"Cell Rep"},{"issue":"1","key":"2512_CR300","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01103-4","volume":"14","author":"T Fu","year":"2021","unstructured":"Fu T, et al. Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response. J Hematol Oncol. 2021;14(1):98.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"2512_CR301","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541\u201350.","journal-title":"Nat Med"},{"issue":"8","key":"2512_CR302","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/s41568-024-00714-6","volume":"24","author":"MA Harris","year":"2024","unstructured":"Harris MA, et al. Towards targeting the breast cancer immune microenvironment. Nat Rev Cancer. 2024;24(8):554\u201377.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2512_CR303","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02255-4","volume":"24","author":"Y Ji","year":"2025","unstructured":"Ji Y, et al. The epigenetic hallmarks of immune cells in cancer. Mol Cancer. 2025;24(1):66.","journal-title":"Mol Cancer"},{"issue":"18","key":"2512_CR304","doi-asserted-by":"publisher","first-page":"7054","DOI":"10.7150\/thno.102037","volume":"14","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, et al. Unlocking the dual role of LSD1 in tumor immunity: innate and adaptive pathways. Theranostics. 2024;14(18):7054\u201371.","journal-title":"Theranostics"},{"key":"2512_CR305","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217182","volume":"600","author":"T Gu","year":"2024","unstructured":"Gu T, et al. Restoration of TFPI2 by LSD1 inhibition suppresses tumor progression and potentiates antitumor immunity in breast cancer. Cancer Lett. 2024;600:217182.","journal-title":"Cancer Lett"},{"issue":"1","key":"2512_CR306","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-03088-1","volume":"23","author":"JS Chen","year":"2023","unstructured":"Chen JS, et al. A novel STAT3\/ NF\u03baB p50 axis regulates stromal-KDM2A to promote M2 macrophage-mediated chemoresistance in breast cancer. Cancer Cell Int. 2023;23(1):237.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"2512_CR307","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02197-3","volume":"23","author":"X Li","year":"2024","unstructured":"Li X, et al. Mutation of lysine-specific demethylase 5 is associated with enhanced tumor immunity and favorable outcomes in pan-cancer immune checkpoint blockade. Mol Cancer. 2024;23(1):281.","journal-title":"Mol Cancer"},{"issue":"9","key":"2512_CR308","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1002\/ijc.25792","volume":"128","author":"JA Coleman","year":"2011","unstructured":"Coleman JA, et al. T cells reactive with HLA-A*0201 peptides from the histone demethylase JARID1B are found in the circulation of breast cancer patients. Int J Cancer. 2011;128(9):2114\u201324.","journal-title":"Int J Cancer"},{"issue":"5","key":"2512_CR309","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109955","volume":"37","author":"L He","year":"2021","unstructured":"He L, et al. Global characterization of macrophage polarization mechanisms and identification of M2-type polarization inhibitors. Cell Rep. 2021;37(5):109955.","journal-title":"Cell Rep"},{"issue":"8","key":"2512_CR310","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110865","volume":"39","author":"M Laviron","year":"2022","unstructured":"Laviron M, et al. Tumor-associated macrophage heterogeneity is driven by tissue territories in breast cancer. Cell Rep. 2022;39(8):110865.","journal-title":"Cell Rep"},{"issue":"1","key":"2512_CR311","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0620-6","volume":"11","author":"A D\u2019Souza","year":"2018","unstructured":"D\u2019Souza A, Spicer D, Lu J. Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer. J Hematol Oncol. 2018;11(1):80.","journal-title":"J Hematol Oncol"},{"issue":"21","key":"2512_CR312","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1158\/0008-5472.CAN-23-4066","volume":"84","author":"YW Li","year":"2024","unstructured":"Li YW, et al. Molecular characterization and classification of HER2-positive breast cancer inform tailored therapeutic strategies. Cancer Res. 2024;84(21):3669\u201383.","journal-title":"Cancer Res"},{"key":"2512_CR313","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143540","author":"H Maadi","year":"2021","unstructured":"Maadi H, et al. Trastuzumab mechanism of action; 20 years of research to unravel a dilemma. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13143540.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"2512_CR314","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.7150\/ijbs.87415","volume":"20","author":"Y He","year":"2024","unstructured":"He Y, et al. tRF-27 competitively binds to G3BPs and activates MTORC1 to enhance HER2 positive breast cancer trastuzumab tolerance. Int J Biol Sci. 2024;20(10):3923\u201341.","journal-title":"Int J Biol Sci"},{"issue":"Suppl 2(Suppl 2","key":"2512_CR315","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2573","volume":"12","author":"E Rivera","year":"2010","unstructured":"Rivera E, Gomez H. Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. Breast Cancer Res. 2010;12(Suppl 2(Suppl 2)):S2.","journal-title":"Breast Cancer Res"},{"issue":"12","key":"2512_CR316","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.15252\/embr.201541011","volume":"16","author":"A Harikumar","year":"2015","unstructured":"Harikumar A, Meshorer E. Chromatin remodeling and bivalent histone modifications in embryonic stem cells. EMBO Rep. 2015;16(12):1609\u201319.","journal-title":"EMBO Rep"},{"issue":"40","key":"2512_CR317","doi-asserted-by":"publisher","first-page":"16061","DOI":"10.1073\/pnas.1315204110","volume":"110","author":"BJ Lesch","year":"2013","unstructured":"Lesch BJ, et al. A set of genes critical to development is epigenetically poised in mouse germ cells from fetal stages through completion of meiosis. Proc Natl Acad Sci USA. 2013;110(40):16061\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2512_CR318","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2016.10.003","volume":"51","author":"ES Villodre","year":"2016","unstructured":"Villodre ES, et al. Roles of OCT4 in tumorigenesis, cancer therapy resistance and prognosis. Cancer Treat Rev. 2016;51:1\u20139.","journal-title":"Cancer Treat Rev"},{"key":"2512_CR319","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2109133119","author":"B Liu","year":"2022","unstructured":"Liu B, et al. BRD4-directed super-enhancer organization of transcription repression programs links to chemotherapeutic efficacy in breast cancer. Proc Natl Acad Sci U S A. 2022. https:\/\/doi.org\/10.1073\/pnas.2109133119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2512_CR320","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.molcel.2005.06.027","volume":"19","author":"MK Jang","year":"2005","unstructured":"Jang MK, et al. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell. 2005;19(4):523\u201334.","journal-title":"Mol Cell"},{"issue":"17","key":"2512_CR321","doi-asserted-by":"publisher","first-page":"6380","DOI":"10.1073\/pnas.0710331105","volume":"105","author":"NP Crawford","year":"2008","unstructured":"Crawford NP, et al. Bromodomain 4 activation predicts breast cancer survival. Proc Natl Acad Sci U S A. 2008;105(17):6380\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7327","key":"2512_CR322","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos P, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067\u201373.","journal-title":"Nature"},{"issue":"7586","key":"2512_CR323","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature16508","volume":"529","author":"S Shu","year":"2016","unstructured":"Shu S, et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature. 2016;529(7586):413\u20137.","journal-title":"Nature"},{"issue":"11","key":"2512_CR324","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/iub.2888","volume":"76","author":"M Ebrahimnezhad","year":"2024","unstructured":"Ebrahimnezhad M, et al. LncRNAs: new players of cancer drug resistance via targeting ABC transporters. IUBMB Life. 2024;76(11):883\u2013921.","journal-title":"IUBMB Life"},{"issue":"2","key":"2512_CR325","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","volume":"21","author":"L Morrison","year":"2024","unstructured":"Morrison L, Loibl S, Turner NC. The CDK4\/6 inhibitor revolution - a game-changing era for breast cancer treatment. Nat Rev Clin Oncol. 2024;21(2):89\u2013105.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"2512_CR326","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","volume":"22","author":"S Goel","year":"2022","unstructured":"Goel S, Bergholz JS, Zhao JJ. Targeting CDK4 and CDK6 in cancer. Nat Rev Cancer. 2022;22(6):356\u201372.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2512_CR327","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2159-8290.CD-22-0416","volume":"13","author":"YM Soto-Feliciano","year":"2023","unstructured":"Soto-Feliciano YM, et al. A molecular switch between mammalian MLL complexes dictates response to Menin-MLL inhibition. Cancer Discov. 2023;13(1):146\u201369.","journal-title":"Cancer Discov"},{"issue":"1","key":"2512_CR328","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27502-2","volume":"12","author":"A D\u2019Oto","year":"2021","unstructured":"D\u2019Oto A, et al. KDM6B promotes activation of the oncogenic CDK4\/6-pRB-E2F pathway by maintaining enhancer activity in MYCN-amplified neuroblastoma. Nat Commun. 2021;12(1):7204.","journal-title":"Nat Commun"},{"issue":"1","key":"2512_CR329","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01462-3","volume":"23","author":"JO Brett","year":"2021","unstructured":"Brett JO, et al. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res. 2021;23(1):85.","journal-title":"Breast Cancer Res"},{"issue":"16","key":"2512_CR330","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s40265-020-01394-w","volume":"80","author":"SE Nunnery","year":"2020","unstructured":"Nunnery SE, Mayer IA. Targeting the PI3K\/AKT\/mTOR pathway in hormone-positive breast cancer. Drugs. 2020;80(16):1685\u201397.","journal-title":"Drugs"},{"issue":"8","key":"2512_CR331","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.ccell.2021.06.001","volume":"39","author":"AB Hanker","year":"2021","unstructured":"Hanker AB, et al. Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2\/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity. Cancer Cell. 2021;39(8):1099-1114.e8.","journal-title":"Cancer Cell"},{"issue":"1","key":"2512_CR332","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0803-3","volume":"17","author":"N Haddadi","year":"2018","unstructured":"Haddadi N, et al. PTEN\/PTENP1: \u201cRegulating the regulator of RTK-dependent PI3K\/Akt signalling\u201d, new targets for cancer therapy. Mol Cancer. 2018;17(1):37.","journal-title":"Mol Cancer"},{"key":"2512_CR333","doi-asserted-by":"publisher","DOI":"10.1172\/JCI183391","author":"S Gold","year":"2024","unstructured":"Gold S, Shilatifard A. Epigenetic therapies targeting histone lysine methylation: complex mechanisms and clinical challenges. J Clin Invest. 2024. https:\/\/doi.org\/10.1172\/JCI183391.","journal-title":"J Clin Invest"},{"issue":"5","key":"2512_CR334","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/med.21955","volume":"43","author":"YQ Song","year":"2023","unstructured":"Song YQ, et al. The role and prospect of lysine-specific demethylases in cancer chemoresistance. Med Res Rev. 2023;43(5):1438\u201369.","journal-title":"Med Res Rev"},{"issue":"38","key":"2512_CR335","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1038\/s41388-024-03125-x","volume":"43","author":"A Nguyen","year":"2024","unstructured":"Nguyen A, et al. Jumonji histone demethylases are therapeutic targets in small cell lung cancer. Oncogene. 2024;43(38):2885\u201399.","journal-title":"Oncogene"},{"issue":"18","key":"2512_CR336","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202100949","volume":"33","author":"X Ji","year":"2021","unstructured":"Ji X, et al. Epigenetic remodeling hydrogel patches for multidrug-resistant triple-negative breast cancer. Adv Mater. 2021;33(18):e2100949.","journal-title":"Adv Mater"},{"issue":"4","key":"2512_CR337","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1021\/acs.jmedchem.5b01758","volume":"59","author":"TE McAllister","year":"2016","unstructured":"McAllister TE, et al. Recent progress in histone demethylase inhibitors. J Med Chem. 2016;59(4):1308\u201329.","journal-title":"J Med Chem"},{"issue":"2","key":"2512_CR338","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/med.22000","volume":"44","author":"HM Liu","year":"2024","unstructured":"Liu HM, et al. LSD1 in drug discovery: from biological function to clinical application. Med Res Rev. 2024;44(2):833\u201366.","journal-title":"Med Res Rev"},{"issue":"1","key":"2512_CR339","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02011-0","volume":"23","author":"CY Li","year":"2024","unstructured":"Li CY, et al. KDM5 family as therapeutic targets in breast cancer: pathogenesis and therapeutic opportunities and challenges. Mol Cancer. 2024;23(1):109.","journal-title":"Mol Cancer"},{"issue":"14","key":"2512_CR340","doi-asserted-by":"publisher","first-page":"9564","DOI":"10.1021\/acs.jmedchem.2c00680","volume":"65","author":"Q Wu","year":"2022","unstructured":"Wu Q, et al. Recent advances with KDM4 inhibitors and potential applications. J Med Chem. 2022;65(14):9564\u201379.","journal-title":"J Med Chem"},{"issue":"1","key":"2512_CR341","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0811-9","volume":"12","author":"Y Fang","year":"2019","unstructured":"Fang Y, Liao G, Yu B. LSD1\/KDM1A inhibitors in clinical trials: advances and prospects. J Hematol Oncol. 2019;12(1):129.","journal-title":"J Hematol Oncol"},{"key":"2512_CR342","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118254","volume":"189","author":"M Nastaranpour","year":"2025","unstructured":"Nastaranpour M, et al. Lysine demethylase 6 (KDM6): a promising therapeutic target in autoimmune disorders and cancer. Biomed Pharmacother. 2025;189:118254.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"2512_CR343","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.cell.2018.06.018","volume":"174","author":"S Mishra","year":"2018","unstructured":"Mishra S, et al. Cross-talk between lysine-modifying enzymes controls site-specific DNA amplifications. Cell. 2018;174(4):803-817.e16.","journal-title":"Cell"},{"key":"2512_CR344","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107354","volume":"208","author":"M Huang","year":"2024","unstructured":"Huang M, et al. Methylation modification of non-histone proteins in breast cancer: an emerging targeted therapeutic strategy. Pharmacol Res. 2024;208:107354.","journal-title":"Pharmacol Res"},{"key":"2512_CR345","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1120911","volume":"14","author":"B Noce","year":"2023","unstructured":"Noce B, et al. LSD1 inhibitors for cancer treatment: focus on multi-target agents and compounds in clinical trials. Front Pharmacol. 2023;14:1120911.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2512_CR346","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.bbrc.2019.05.118","volume":"515","author":"Y Jin","year":"2019","unstructured":"Jin Y, et al. Kdm1a promotes SCLC progression by transcriptionally silencing the tumor suppressor Rest. Biochem Biophys Res Commun. 2019;515(1):214\u201321.","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"2512_CR347","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1016\/j.jtho.2019.06.021","volume":"14","author":"TM Bauer","year":"2019","unstructured":"Bauer TM, et al. Phase I, open-label, dose-escalation study of the safety, pharmacokinetics, pharmacodynamics, and efficacy of GSK2879552 in relapsed\/refractory SCLC. J Thorac Oncol. 2019;14(10):1828\u201338.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"2512_CR348","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1097\/CAD.0000000000001514","volume":"34","author":"C Chandhasin","year":"2023","unstructured":"Chandhasin C, et al. TACH101, a first-in-class pan-inhibitor of KDM4 histone demethylase. Anticancer Drugs. 2023;34(10):1122\u201331.","journal-title":"Anticancer Drugs"},{"issue":"12","key":"2512_CR349","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0271145","volume":"17","author":"SA Gilmore","year":"2022","unstructured":"Gilmore SA, et al. Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus. PLoS One. 2022;17(12):e0271145.","journal-title":"PLoS One"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02512-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02512-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02512-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:38:23Z","timestamp":1781624303000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-025-02512-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":349,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2512"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02512-6","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}